Detoxifying and synergistic chemotherapeutic drug carrier structure triglyceride composition as well as preparation method and application thereof

By preparing a structured triglyceride composition and using it in combination with chemotherapy drugs, the problem of toxic side effects of chemotherapy drugs was solved, and the effects of improving chemotherapy efficacy, improving quality of life, and prolonging survival were achieved.

CN121826075APending Publication Date: 2026-04-10HEBEI KANGRUIDA LIPID CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202511886292.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-15
Publication Date
2026-04-10

AI Technical Summary

Technical Problem

Existing chemotherapy drugs have serious toxic side effects when treating malignant tumors, affecting patients' quality of life and survival time. There is a lack of effective non-toxic or low-toxicity chemotherapy regimens.

Method used

By preparing a structural triglyceride composition, utilizing transesterification and enzyme catalysis, and combining specific oils and lipases, a chemotherapy drug carrier structural triglyceride composition with detoxification and efficacy-enhancing effects is prepared for use in combination with chemotherapy drugs.

Benefits of technology

Significantly reduce the toxic side effects of chemotherapy drugs, improve the efficacy of chemotherapy, prolong survival, enhance the quality of life of patients, provide non-toxic or low-toxicity chemotherapy rehabilitation programs, reduce medical expenses, and enable cancer patients to receive non-toxic chemotherapy at home.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121826075A_ABST
    Figure CN121826075A_ABST
Patent Text Reader

Abstract

The invention relates to a detoxifying and synergistic chemotherapeutic drug carrier structure triglyceride composition as well as a preparation method and application thereof, belonging to the technical field of biology. The preparation method comprises the following steps: carrying out first ester exchange reaction on mixed oil 1 and lipase 1 to prepare a product 1; the mixed oil 2 and lipase 2 are subjected to a second ester exchange reaction, deodorization and enzyme deactivation are carried out, and a structure triglyceride composition is prepared; wherein the oil material 1 comprises highly unsaturated fatty acid and glycerol; the oil material 2 comprises the product 1, r-linolenic acid, nervonic acid and pinolenic acid. The triglyceride composition with the structure has the effects of detoxifying, improving leukocyte level, erythrocyte level and septicemia after chemotherapy, preventing alopecia and resisting tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of biotechnology, and in particular to a triglyceride composition of a chemotherapy drug carrier structure that enhances detoxification and efficacy, as well as its preparation method and application. Background Technology

[0002] For decades, structured triglyceride fatty lactate parenteral nutrition has been a primary means of saving the lives of critically ill patients in clinical practice, with the aim of maintaining vital signs. It is used for cancer patients who cannot eat after surgery and for end-of-life care, but its use is limited to the nutritional level.

[0003] In the treatment of malignant tumors, chemotherapy drugs are mainly used to kill cancer cells and prevent tumor growth and metastasis. However, they have toxic side effects, causing damage to benign cells and multiple organs, such as: hair loss, pericardial edema, cardiac arrhythmia, slowed blood flow / ischemia, hemorrhage and thrombosis, brain (brain shrinkage, brain degeneration), intestinal abnormalities, trunk / tail / back (bending edema), intramuscular / segmental (degeneration), kidney (renal edema), behavioral abnormalities, generalized ulcers, muscle weakness, generalized edema, muscle atrophy, chest pain, and a sharp drop in white blood cells. These side effects cause severe fear in patients, reduce their quality of life, lead to more severe illness despite treatment, make discharge difficult, and hinder survival. Under these circumstances, the use of structured triglyceride fat emulsions for the rehabilitation of cancer patients has limitations.

[0004] Currently, 293 medical food certificates have been obtained by domestic and foreign companies, most of which meet the requirements for medical food components. However, there are still no effective solutions for clinically urgent needs for non-toxic chemotherapy drugs or rapid relief of chemotherapy toxicity. Based on this, this application is submitted. Summary of the Invention

[0005] Based on this, one or more embodiments of this application provide a triglyceride composition with a detoxifying and enhancing chemotherapeutic drug carrier structure, its preparation method, and its application. The technical solutions include the following:

[0006] One or more embodiments of this application provide a method for preparing a structural triglyceride composition, the preparation method comprising the following steps:

[0007] Mixed oil 1 and lipase 1 undergo a first transesterification reaction to prepare product 1; and,

[0008] Mixed oilseed 2 and lipase 2 undergo a second transesterification reaction to deodorize and inactivate the enzyme, preparing a structured triglyceride composition; wherein...

[0009] The oil 1 comprises highly unsaturated fatty acids and glycerol;

[0010] The oilseed 2 includes the product 1, γ-linolenic acid, nervonic acid, and pinolenic acid;

[0011] Optionally, the highly unsaturated fatty acids are added in the form of one or more of fish oil extracts, reduced fish oil, and polyene fish oil;

[0012] Optionally, the γ-linolenic acid is added in the form of one or more of borage seed oil, evening primrose oil, blackcurrant oil, and fermented γ-linolenic acid;

[0013] Optionally, the nervonic acid is added in the form of one or more of the following: *Sapindus mukorossi* oil, *Acer truncatum* seed oil, and *Gnaphalium affine*.

[0014] Optionally, the pinolenic acid is added in the form of pine nut oil.

[0015] In some embodiments of this application, the preparation method satisfies one or more of the following conditions:

[0016] (A1) By weight, the oil 1 comprises: 8 to 20 parts of the polyene fish oil and 0.5 to 13 parts of glycerol;

[0017] (A2) The amount of lipase 1 added is 3% to 8% of the weight of oil 1;

[0018] (A3) The lipase 1 includes an immobilized lipase; and,

[0019] (A4) The conditions for the first transesterification reaction include: vacuum degree of 50~200 Pa, temperature of 55~70℃, and time of 10~28h;

[0020] Optionally, the lipase 1 includes one or more of the following: modified Aspergillus oryzae immobilized lipase, Candida antarcticis immobilized lipase, and IMNE0100 immobilized lipase.

[0021] In some embodiments of this application, the preparation method satisfies one or more of the following conditions:

[0022] (A5) By weight, the oilseed 2 comprises: 2.5 to 4.5 parts of the product 1, 4.5 to 6.0 parts of borage seed oil, 0.2 to 1 part of pine nut oil and 0.2 to 2 parts of *Sapindus mukorossi* oil; or, 2.5 to 4.5 parts of the product 1, 4.5 to 6.0 parts of borage seed oil and 0.2 to 1.5 parts of *Acer truncatum* seed oil;

[0023] (A6) The amount of lipase 2 added is 3% to 8% of the weight of the oilseed 2;

[0024] (A7) The lipase 2 includes an immobilized lipase; and,

[0025] (A8) The conditions for the second transesterification reaction include: vacuum degree of 5~200 Pa, temperature of 55~70℃, and time of 20~26 h;

[0026] Optionally, the lipase 2 includes one or more of the following: modified Aspergillus oryzae immobilized lipase, Candida antarcticis immobilized lipase, and IMNE0100 immobilized lipase.

[0027] One or more embodiments of this application provide a structural triglyceride composition prepared by the preparation method described above.

[0028] One or more embodiments of this application provide the use of a structural lipid as a chemotherapeutic drug detoxification and efficacy enhancer;

[0029] The structural lipids include one or more of structural lipids B1 to structural lipids B4;

[0030] Structured lipid B1 is the structured triglyceride composition according to claim 4;

[0031] Structural lipid B2 is a polyunsaturated fatty acid structural lipid, prepared by the following method:

[0032] (1) Transesterification reaction: The raw materials and transesterification enzyme are reacted in a reactor to obtain the reaction product. The vacuum conditions are 50~200Pa, the reaction temperature is 40~90℃, and the reaction time is 8~48h.

[0033] (2) Refining reaction: The reaction product obtained in step (1) is deacidified, deodorized and enzyme inactivated by distillation, and then finely filtered to obtain polyunsaturated fatty acid structure lipids.

[0034] The raw materials include at least oils containing gamma-linolenic acid and oils containing eicosapentaenoic acid and docosahexaenoic acid; the raw materials also include one or more of the following: Acer truncatum seed oil, garlic fruit oil, pine nut oil, coconut oil, palm oil, and Moringa seed oil.

[0035] Structural lipid B3 was prepared by the following method:

[0036] Structured lipid B3 was obtained by reacting highly unsaturated fatty acids, glycerol, and transesterase.

[0037] The highly unsaturated fatty acids mentioned herein are oils containing EPA and DHA;

[0038] The reaction conditions are: vacuum, reaction temperature 50℃~80℃, and reaction time 15~48h;

[0039] Structural lipid B4 is an 18-24 carbon polyunsaturated fatty acid structural lipid; optionally, the raw materials for preparing the 18-24 carbon polyunsaturated fatty acid structural lipid are selected from one or more of structural lipids containing linoleic acid, structural lipids containing γ-linolenic acid, structural lipids containing EPA, and structural lipids containing DHA.

[0040] Optionally, the structural lipid B4 is prepared by the following method:

[0041] Mixed oil 4 and lipase 4 undergo a fourth transesterification reaction to inactivate the enzyme and prepare structural lipid B4.

[0042] The oilseed 4 includes borage seed oil, fish oil, and thistle seed oil;

[0043] Optionally, the method for preparing the structural lipid B4 satisfies one or more of the following conditions:

[0044] (B41) By weight, the oilseed 4 comprises 45-60 parts borage seed oil, 30-40 parts fish oil and 10-20 parts thistle seed oil;

[0045] (B42) The lipase 4 includes an immobilized enzyme;

[0046] (B43) The amount of lipase 4 added is 3.5% to 4.5% of the weight of the oil 4;

[0047] (B44) The conditions for the fourth transesterification reaction include: vacuum degree of 50~200 Pa, temperature of 55~70℃, and time of 30~40 h;

[0048] Optionally, the lipase 4 includes one or more of IMNE-100 immobilized lipase and Novozymes 435 immobilized lipase.

[0049] One or more embodiments of this application provide a composition comprising:

[0050] Structural lipids, as defined above; and,

[0051] Chemotherapy drugs;

[0052] The composition is a combination drug composition or mixture.

[0053] In some embodiments of this application, the composition is further fortified with a nutrient fortifier, including Haematococcus pluvialis oil;

[0054] Optionally, the amount of Haematococcus pluvialis oil added is 1 to 3‰ of the weight of the structural lipid.

[0055] In some embodiments of this application, the weight ratio of the structural lipid to the chemotherapeutic drug is (96~100):(3~4).

[0056] In some embodiments of this application, the composition also contains an emulsifier;

[0057] Optionally, the amount of the emulsifier added is 2% to 4% of the weight of the structural lipid or the composition;

[0058] Optionally, the emulsifier includes one or more of the following: sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80), polyoxyethylene (20) sorbitan monooleate (Tween 80), polyoxyethylene (20) sorbitan monolaurate (Tween 20), mono- and diglycerides of fatty acids, polyglycerol fatty acids, polyethylene glycol fatty acids, and polyglycerol ricinoleate.

[0059] In some embodiments of this application, the composition is further provided with medium- and long-chain fatty acids;

[0060] Optionally, the method for preparing the medium- and long-chain fatty acids includes:

[0061] (a) The purified medium-chain fatty acid triglycerides and the purified 14-24 carbon long-chain fatty acid triglycerides were put into a reactor, lipase and vitamin E catalyst were added, and transesterification reaction was carried out at a temperature of 40-85℃, a vacuum of 5-200 Pa, for 15-34 hours. The reaction was then terminated to obtain material 1.

[0062] (b) The material 1 obtained in step (a) is purified at a temperature of 190~260°C with dry water vapor to remove acid, deodorize, remove medium chain residues and deactivate enzymes to obtain the target product, high-purity medium and long chain fatty acid oil.

[0063] Optionally, the weight ratio of the structural lipid or the composition to the medium- and long-chain fatty acid oil is (1~9):(1~4).

[0064] Details of one or more embodiments of this application are set forth in the following description, and other features, objects, and advantages of this application will become apparent from the specification and its claims. Attached Figure Description

[0065] To more clearly illustrate the technical solutions in the embodiments of this application and to more completely understand this application and its beneficial effects, the drawings used in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0066] Figure 1A and Figure 1B The image shows the toxicity of cisplatin-treated zebrafish treated with triglycerides after 72 hours of treatment with a chemotherapy drug carrier structure that enhances detoxification and efficacy.

[0067] Figure 2A and Figure 2BThe image shows the toxicity of cyclophosphamide treated with triglycerides in zebrafish 72 hours after treatment with cyclophosphamide to enhance the detoxification and efficacy of the chemotherapy drug carrier.

[0068] Figure 3A and Figure 3B The image shows the toxicity of triglyceride-based chemotherapy drug carriers after 72 hours of methotrexate treatment in zebrafish with tumors, following treatment with triglyceride.

[0069] Figure 4A and Figure 4B The image shows the toxicity of a chemotherapy drug carrier structure with detoxification and enhanced efficacy after treatment of zebrafish with chlorofazimine for 72 hours.

[0070] Figure 5A and Figure 5B The image shows the toxicity of tamoxifen-treated tumor zebrafish after 72 hours of treatment with a triglyceride-based chemotherapy drug carrier structure that enhances detoxification and efficacy.

[0071] Figure 6A and Figure 6B The image shows the toxicity of a chemotherapy drug carrier structure with detoxification and enhanced efficacy after treatment of zebrafish with doxorubicin hydrochloride for 72 hours.

[0072] Figure 7A and Figure 7B The image shows the toxicity of imatinib-treated zebrafish 72 hours after treatment with a triglyceride-based chemotherapy drug carrier structure for detoxification and efficacy enhancement.

[0073] Figure 8A and Figure 8B The image shows the toxicity of a chemotherapy drug carrier structure with detoxification and enhanced efficacy after treatment of zebrafish with tumors with etoposide using triglyceride for 72 hours.

[0074] Figure 9A and Figure 9B The diagram shows the toxicity of paclitaxel-treated zebrafish with tumors after 72 hours of treatment with a chemotherapeutic drug carrier structure that enhances detoxification and efficacy.

[0075] Figure 10A and Figure 10B The image shows the toxicity of a chemotherapy drug carrier structure with detoxification and enhanced efficacy after treatment with 5-FU for tumors in zebrafish for 72 hours.

[0076] Figure 11A and Figure 11B The figure shows the number of neutrophils in the tail vein of zebrafish after treatment with triglycerides for 48 h to enhance the detoxification and efficacy of the chemotherapy drug carrier.

[0077] Figure 12A and Figure 12B The image shows the fluorescence intensity of zebrafish thymus T cells after treatment with triglycerides for 48 h to enhance the detoxification and efficacy of the chemotherapy drug carrier.

[0078] Figure 13A and Figure 13B The figure shows the number of macrophages in the tail vein of zebrafish after treatment with triglycerides for 48 h to enhance the detoxification and efficacy of the chemotherapy drug carrier.

[0079] Figure 14A and Figure 14B The image shows the staining intensity of erythrocytes from the heart of zebrafish after treatment with triglycerides for 48 h to enhance the detoxification and efficacy of the chemotherapy drug carrier.

[0080] Figure 15A and Figure 15B The diagram shows the structure of a chemotherapy drug carrier that enhances detoxification and efficacy, and the number of neutrophils in the heart of zebrafish after treatment with triglycerides.

[0081] Figure 16 The diagram shows the blood flow velocity in zebrafish after treatment with triglycerides, which enhances the detoxification and efficacy of the chemotherapy drug carrier.

[0082] Figure 17A and Figure 17B The image shows the fluorescence intensity of zebrafish myeloid tumor cells after treatment with triglycerides, a chemotherapy drug carrier structure that enhances detoxification and efficacy, for 48 h.

[0083] Figure 18A and Figure 18B The image shows the fluorescence intensity of zebrafish lymphoma cells after treatment with triglycerides, a chemotherapy drug carrier structure that enhances detoxification and efficacy, for 48 h. Detailed Implementation

[0084] The present application will be further described in detail below with reference to the accompanying drawings, embodiments, and examples. It should be understood that these embodiments and examples are for illustrative purposes only and are not intended to limit the scope of the present application. The purpose of providing these embodiments and examples is to enable a more thorough and comprehensive understanding of the disclosure of the present application. It should also be understood that the present application can be implemented in many different forms and is not limited to the embodiments and examples described herein. Those skilled in the art can make various modifications or alterations without departing from the spirit of the present application, and the equivalent forms obtained also fall within the protection scope of the present application. Furthermore, numerous specific details are set forth in the following description to provide a fuller understanding of the present application. It should be understood that the present application can be implemented without one or more of these details.

[0085] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein in the specification of this application is for descriptive purposes only and is not intended to be limiting of the application.

[0086] Unless otherwise stated or in case of contradiction, the terms or phrases used herein shall have the following meanings:

[0087] The terms "and / or," "or / and," and "and / or" as used herein include any one of two or more of the related listed items, as well as any and all combinations of the related listed items. These arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or," "or / and," and "and / or," it should be understood that in this application, the technical solution undoubtedly includes technical solutions connected by "logical AND," and also undoubtedly includes technical solutions connected by "logical OR." For example, "A and / or B" includes three parallel solutions: A, B, and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, a technical solution that is connected by "logical OR"), as well as any and all combinations of A, B, C, and D, that is, combinations of any two or three of A, B, C, and D, and also combinations of all four of A, B, C, and D (that is, a technical solution that is connected by "logical AND").

[0088] In this application, the terms "multiple", "various", "multiple times", "multi-dimensional", etc., unless otherwise specified, refer to a quantity greater than or equal to 2. For example, "one or more" means one or more than or equal to two.

[0089] The terms “combinations of,” “any combination of,” and “any combination of” used in this article include all suitable combinations of any two or more of the listed items.

[0090] In this document, the term "suitable" as used in phrases such as "suitable combination," "suitable method," and "any suitable method" refers to the ability to implement the technical solution of this application, solve the technical problem of this application, and achieve the expected technical effect of this application.

[0091] In this document, terms such as “preferred,” “better,” “more suitable,” and “ideal” are merely used to describe implementation methods or examples that achieve better results, and should be understood not to limit the scope of protection of this application.

[0092] In this application, terms such as "further," "even further," and "particularly" are used to describe purposes and indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0093] In this application, "optionally," "optionally," and "optional" mean that something is optional, that is, it means that it is selected from either "with" or "without." If there are multiple "optional" entries in a technical solution, unless otherwise specified, and there are no contradictions or mutual constraints, each "optional" entry shall be independent.

[0094] In this application, the terms "first aspect," "second aspect," "third aspect," "fourth aspect," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or quantity, nor should they be construed as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first," "second," "third," "fourth," etc., serve only as a non-exhaustive enumeration and should be understood not to constitute a closed limitation on quantity.

[0095] In this application, the technical features described in an open-ended manner include both closed technical solutions consisting of the listed features and open technical solutions that include the listed features.

[0096] In this application, numerical intervals (i.e., numerical ranges) are involved. Unless otherwise specified, the selected numerical distributions within the aforementioned numerical intervals are considered continuous and include the two endpoints (i.e., the minimum and maximum values) of the numerical range, as well as every value between these two endpoints. Unless otherwise specified, when a numerical interval refers only to integers within that interval, it includes the two endpoint integers of the numerical range, as well as every integer between the two endpoints. In this document, this is equivalent to directly listing every integer. For example, if t is an integer selected from 1 to 10, it means that t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. Furthermore, when multiple ranges are provided to describe features or characteristics, these ranges can be merged. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges to which they are included.

[0097] Unless otherwise specified, the temperature parameters in this application are permitted to be either constant-temperature treatment or variations within a certain temperature range. It should be understood that the constant-temperature treatment allows temperature fluctuations within the precision range of the instrument control, such as ±5℃, ±4℃, ±3℃, ±2℃, or ±1℃.

[0098] In this application, %(w / w) and wt% both represent weight percentage, %(v / v) refers to volume percentage, and %(w / v) refers to mass-volume percentage.

[0099] All references to this application are incorporated herein by reference as if each document were individually incorporated herein by reference. Unless they conflict with the purpose and / or technical solution of this application, all cited references are incorporated herein by reference in their entirety and for all purposes. When references are cited in this application, the definitions of relevant technical features, terms, nouns, phrases, etc., are also incorporated herein by reference. Examples and preferred embodiments of the cited technical features may also be incorporated herein by reference, but only to the extent that they enable the implementation of this application. It should be understood that when the cited content conflicts with the description in this application, this application shall prevail or modifications shall be made adaptably to the description in this application.

[0100] In a first aspect, this embodiment provides a method for preparing a structural triglyceride composition, the method comprising the following steps:

[0101] Mixed oil 1 and lipase 1 undergo a first transesterification reaction to prepare product 1; and,

[0102] Mixed oilseed 2 and lipase 2 undergo a second transesterification reaction to deodorize and inactivate the enzyme, preparing a structured triglyceride composition; wherein...

[0103] The oil 1 comprises highly unsaturated fatty acids and glycerol;

[0104] The oil 2 includes the product 1, γ-linolenic acid, nervonic acid, and pinolenic acid.

[0105] Optionally, the highly unsaturated fatty acids are added in the form of one or more of fish oil extracts, reduced fish oil, and polyene fish oil.

[0106] Optionally, the γ-linolenic acid is added in the form of one or more of borage seed oil, evening primrose oil, blackcurrant oil, and fermented γ-linolenic acid.

[0107] Optionally, the nervonic acid is added in the form of one or more of the following: *Sapindus mukorossi* oil, *Acer truncatum* seed oil, and *Gnaphalium affine*.

[0108] Optionally, the pinolenic acid is added in the form of pine nut oil.

[0109] Fish oil with high unsaturated fatty acid content (EPA+DHA greater than 50-95%), borage seed oil, evening primrose oil or fermented gamma-linolenic acid content (8-50%), saxifrage oil, maple seed oil nervonic acid content (3-6%), medium-chain fatty acid content (12-40%), medium and long-chain fatty acid triglyceride content (18-80%).

[0110] The reactor for transesterification is an ultrasonic packed column reactor, an ultrasonic bed reactor, or a commercially available reactor.

[0111] In some embodiments of this application, the preparation method satisfies one or more of the following conditions:

[0112] (A1) By weight, the oil 1 comprises: 8 to 20 parts of the polyene fish oil and 0.5 to 13 parts of glycerol;

[0113] (A2) The amount of lipase 1 added is 3% to 8% of the weight of oil 1, for example, 3%, 4%, 5%, 6%, 7%, 8%;

[0114] (A3) The lipase 1 includes an immobilized lipase; and,

[0115] (A4) The conditions for the first transesterification reaction include: vacuum degree of 50~200 Pa, temperature of 55~70℃, and time of 10~28 h; vacuum degree for example is 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 Pa, temperature for example is 55, 60, 65, 70℃, and time for example is 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 h;

[0116] Optionally, the lipase 1 includes one or more of the following: modified Aspergillus oryzae immobilized lipase, Candida antarcticis immobilized lipase, and IMNE0100 immobilized lipase.

[0117] In some embodiments of this application, the preparation method satisfies one or more of the following conditions:

[0118] (A5) By weight, the oilseed 2 comprises: 2.5 to 4.5 parts of the product 1, 4.5 to 6.0 parts of borage seed oil, 0.2 to 1 part of pine nut oil and 0.2 to 2 parts of *Sapindus mukorossi* oil; or, 2.5 to 4.5 parts of the product 1, 4.5 to 6.0 parts of borage seed oil and 0.2 to 1.5 parts of *Acer truncatum* seed oil;

[0119] (A6) The amount of lipase 2 added is 3% to 8% of the weight of the oil 2, for example, 3%, 4%, 5%, 6%, 7%, 8%;

[0120] (A7) The lipase 2 includes an immobilized lipase; and,

[0121] (A8) The conditions for the second transesterification reaction include: a vacuum of 5~200 Pa, a temperature of 55~70℃, and a time of 20~26 h; for example, vacuum of 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 Pa, temperature of 55, 60, 65, 70℃, and time of 10, 12, 14, 16, 18, 20, 22, 24, 26 h.

[0122] Optionally, the lipase 2 includes one or more of the following: modified Aspergillus oryzae immobilized lipase, Candida antarcticis immobilized lipase, and IMNE0100 immobilized lipase.

[0123] The structured triglyceride composition prepared in this application contains 18-32% EPA+DHA, 7-15% γ-linolenic acid, 0.5-1% nervonic acid, and the content of fatty acids at the sn-2 position increases from 95% to 99%. The detoxifying components are mainly determined by three components: the total amount of fatty acids at the sn-2 position, which also determines the absorption rate; the total amount of EPA+DHA+γ-linolenic acid+nervonic acid+pinolenic acid; and 15-30% Omega-3, 15-40% omega-6, and 10-25% omega-9. The structured triglyceride composition of this application consists of: 15-70% eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA), 0.01-4% nervonic acid (C24:1), and 6-40% γ-linolenic acid.

[0124] This application relates to a biotechnology for synthesizing structural triglyceride fatty acids C16-24 and C8-24. Using lipase as a catalyst, a structural triglyceride composition is prepared. When used in different application scenarios, it can reduce the toxicity and complications of chemotherapy drugs, improve the efficacy of chemotherapy and quality of life, prolong survival, reduce medical investment, and provide precise solutions.

[0125] This application integrates the following technologies: preparation technology of polyunsaturated fatty acid structured lipids, anti-tumor growth and cancer cell migration inhibition technology, structured triglyceride fat emulsification technology and water-emulsification technology of structured triglyceride fat emulsion, and oral structured triglyceride fat emulsion technology. Cancer patients can undergo non-toxic chemotherapy at home, eliminating the risk of complications, reducing fear of chemotherapy, achieving low-toxicity or non-toxic recovery in a comfortable environment, improving quality of life, prolonging survival, and having significant economic implications for saving treatment costs. It generates new social value for pharmaceutical innovation, improves patients' well-being, provides precise solutions for the effective use of hospital beds, and changes the landscape of malignant disease treatment.

[0126] The structured triglyceride composition is mixed with Haematococcus pluvialis oil and chemotherapy drugs, and compressed into soft capsules. It plays a role in detoxification during chemotherapy and can be used as a formulation for multiple scenarios where oral enteral nutrition and chemotherapy coexist.

[0127] A structural triglyceride composition is mixed with a medium- and long-chain structural triglyceride chemotherapy drug, and egg yolk lecithin, water, glycerol, and sodium hydroxide are added to prepare an emulsion, which is used as a preparation for injecting antidote chemotherapy drugs and parenteral nutrition.

[0128] A structured triglyceride composition, mixed with medium- and long-chain fatty acid structured triglycerides and chemotherapy drugs, and with the addition of a compound emulsifier, is prepared as an oral structured fat emulsion for outpatient home care. Its key feature is that it can be easily mixed with water and shaken to form an emulsion, making it convenient to carry and improving the patient's dietary intake. The main purpose of adding medium- and long-chain fatty acid structured triglycerides to the structured lipids is to meet the high energy and nutritional needs of patients with malignant diseases. The purpose of preparing it as an emulsion is to meet the specific osmotic pressure and pH requirements of individual patients, as well as the specific requirements for daily fat intake. It also meets the comprehensive treatment plan for sarcopenia and systemic inflammation in severe SU patients.

[0129] This application represents a further innovation based on the imported drug structural triglyceride JX20070100, meeting the essential conditions for obtaining a production license. It also complies with the fatty acid liquid functional requirements outlined in the clinical application consensus of GB29922-2013, a standard for special medical purpose oncology complete nutritional formula foods.

[0130] A second aspect of this application provides a structural triglyceride composition prepared by the aforementioned preparation method.

[0131] A third aspect of this application provides the use of structured lipids as a chemotherapeutic drug detoxification and efficacy enhancer.

[0132] The structural lipids include one or more of structural lipids B1 to B4.

[0133] In some examples of this application, the structural lipid B1 is the structural triglyceride composition provided in the second aspect.

[0134] In some examples of this application, structural lipid B2 is a polyunsaturated fatty acid structural lipid, prepared by the following method:

[0135] (1) Transesterification reaction: The raw materials and transesterification enzyme are reacted in a reactor to obtain the reaction product. The vacuum conditions are 50~200 Pa, the reaction temperature is 40~90℃, and the reaction time is 8~48h. The vacuum degree is, for example, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 Pa, the temperature is, for example, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90℃, and the time is, for example, 8, 10, 20, 25, 30, 32, 34, 36, 38, 40, 45, 48h.

[0136] (2) Refining reaction: The reaction product obtained in step (1) is deacidified, deodorized and enzyme inactivated by distillation, and then finely filtered to obtain polyunsaturated fatty acid structure lipids.

[0137] The raw materials include at least oils containing gamma-linolenic acid and oils containing eicosapentaenoic acid and docosahexaenoic acid; the raw materials also include one or more of the following: Acer truncatum seed oil, garlic fruit oil, pine nut oil, coconut oil, palm oil, and Moringa seed oil.

[0138] Optionally, in the method for preparing structural lipid B2, the oil containing γ-linolenic acid is a triglyceride or ethyl ester oil; the triglyceride or ethyl ester oil containing γ-linolenic acid is one or more of evening primrose oil, borage oil, and fermented γ-linolenic acid oil; the oil containing eicosapentaenoic acid and docosahexaenoic acid is one or more of fish oil, reduced fish oil, fish oil extract, polyene fish oil, seal oil, and algal oil.

[0139] Optionally, in the method for preparing structural lipid B2, the evening primrose oil contains 20% to 90% γ-linolenic acid by weight, for example, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%; the borage oil contains 20% to 90% γ-linolenic acid by weight, for example, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%; and the fermented γ-linolenic acid oil contains 20% to 60% γ-linolenic acid by weight, for example, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60%.

[0140] Optionally, in the preparation method of structural lipid B2, the fish oil contains 10% to 80% eicosapentaenoic acid (EPA) and docosahexaenoic acid (DPA) by weight; the reduced fish oil contains 15% to 85% EPA and 10% to 85% DPA; the polyene fish oil contains 40% to 95% EPA and DPA; the seal oil contains more than 15% EPA and DPA and more than 4% DPA; and the algal oil contains more than 30% EPA and 15% to 45% DPA.

[0141] Optionally, in the method for preparing structural lipid B2, the weight ratio of the total weight of eicosapentaenoic acid and docosahexaenoic acid in the raw materials in step (1) to the weight of γ-linolenic acid is 1:1, 1:2, 1:3, 1:4, 1:5, 1:9, 2:1, 3:1 or 4:1.

[0142] Optionally, in the method for preparing structural lipid B2, the transesterification enzyme in step (1) is one or more of modified Aspergillus oryzae immobilized lipase or Candida antarctica immobilized lipase.

[0143] Optionally, in the method for preparing structural lipid B2, the added weight of the transesterification enzyme in step (1) is 2% to 10% of the weight of the raw material.

[0144] Optionally, in the method for preparing structural lipid B2, the reactor in step (1) is one or more of the following: an immobilized enzyme ultrasonic packed column reactor, an immobilized enzyme ultrasonic bed reactor, a stirred reactor, a closed container reactor, and a reactor with a lipase collection device.

[0145] Optionally, in the method for preparing structural lipid B2, the steam flash temperature during the flash distillation deacidification in step (2) is 140°C, the steam flash temperature during deodorization is 180°C, and the steam flash temperature during enzyme inactivation is 220°C; the vacuum degree during the steam flash distillation in each step (2) of the distillation deacidification, deodorization, and enzyme inactivation is 10~200Pa, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200Pa.

[0146] The preparation of structural lipid B2, as described in the various examples of patent document 201811158595.8, alleviates acute and chronic respiratory distress syndromes of COPD.

[0147] In some examples of this application, structural lipid B3 is prepared by the following methods:

[0148] Structured lipid B3 was obtained by reacting highly unsaturated fatty acids, glycerol, and transesterase.

[0149] The highly unsaturated fatty acids mentioned herein are oils containing EPA and DHA;

[0150] The reaction conditions are: vacuum, reaction temperature 50℃~80℃, and reaction time 15~48h; for example, the reaction temperature is 50, 55, 60, 65, 70, 75, 80℃, and the time is 15, 20, 25, 30, 35, 40, 45, 48h.

[0151] Optionally, in the preparation method of structural lipid B3, the highly unsaturated fatty acids are derived from one or more of fish oil, fish oil extract, and polyene fish oil; optionally, the content of EPA+DHA in the highly unsaturated fatty acids is 30% to 98%, for example, 30%, 35%, 40%, 45%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%.

[0152] Optionally, in the method for preparing structural lipid B3, the transesterification enzyme is one or more of Aspergillus oryzae lipase, CALB lipase, Candida antarcticis lipase, immobilized lipase Novozym 435, Lipozyme RM, Lipozyme TM, and Lipozyme IM.

[0153] Optionally, in the method for preparing structural lipid B3, the reactor used for transesterification is selected from one or more of the following: an immobilized enzyme ultrasonic packed column reactor, an immobilized enzyme ultrasonic bed reactor, and a reactor with a lipase collection device.

[0154] The preparation of structural lipid B3, as described in the various examples of patent document 202110289998.1, can inhibit tumor growth and cancer cell migration.

[0155] In some examples of this application, structural lipid B4 is an 18-24 carbon polyunsaturated fatty acid structural lipid; optionally, the raw materials for preparing the 18-24 carbon polyunsaturated fatty acid structural lipid are selected from one or more of structural lipids containing linoleic acid, structural lipids containing γ-linolenic acid, structural lipids containing EPA, and structural lipids containing DHA.

[0156] Optionally, the structural lipid B4 is prepared by the following method:

[0157] Mixed oil 4 and lipase 4 undergo a fourth transesterification reaction to inactivate the enzyme and prepare structural lipid B4.

[0158] The oilseed 4 includes borage seed oil, fish oil, and thistle seed oil;

[0159] Optionally, the method for preparing the structural lipid B4 satisfies one or more of the following conditions:

[0160] (B41) By weight, the oilseed 4 comprises 45-60 parts borage seed oil, 30-40 parts fish oil and 10-20 parts thistle seed oil;

[0161] (B42) The lipase 4 includes an immobilized enzyme;

[0162] (B43) The amount of lipase 4 added is 3.5% to 4.5% of the weight of the oil 4, for example, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 4.1%, 4.2%, 4.3%, 4.4%, or 4.5%.

[0163] (B44) The conditions for the fourth transesterification reaction include: a vacuum of 50-200 Pa, a temperature of 55-70 °C, and a time of 30-40 h; for example, vacuums of 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, and 200 Pa, temperatures of 55, 60, 65, and 70 °C, and times of 30, 32, 34, 36, 38, and 40 h.

[0164] Optionally, the lipase 4 includes one or more of IMNE-100 immobilized lipase and Novozymes 435 immobilized lipase.

[0165] The preparation of structural lipid B4, such as the polyunsaturated fatty acid structural lipids described in the various embodiments of patent document 202211535954.3, has a good antitoxic effect when added to or used in combination with chemotherapeutic drugs.

[0166] A fourth aspect of this application provides a composition comprising:

[0167] Structural lipids, as defined in the third aspect; and,

[0168] Chemotherapy drugs;

[0169] The composition is a combination drug composition or mixture.

[0170] The structural lipids mentioned in this application, or the structural fat emulsions prepared using the structural lipids, can be products packaged separately from the chemotherapy drugs, or they can be mixtures prepared by mixing with the chemotherapy drugs. In the former case, they are used in combination with the chemotherapy drugs; in the latter case, the mixture does not need to be used in combination with the chemotherapy drugs.

[0171] Chemotherapy drugs mainly include: 1. Cytotoxins; 2. Antimetabolites; 3. Antibiotics; 4. Alkaloids; 5. Hormones and anti-hormones; 6. Molecularly targeted drugs; 7. Improving immune levels during chemotherapy and preventing a sharp drop in white blood cells; 8. Eliminating systemic inflammation, preventing sepsis, improving the efficacy evaluation of white blood cell and red blood cell levels after chemotherapy, improving the efficacy evaluation of myeloid leukemia tumor models, and improving the efficacy evaluation of lymphocytic leukemia tumors, and have achieved good validation.

[0172] Cytotoxic drugs: such as cyclophosphamide, nitrogen mustard, carmustine, busulfan, lomustine, 5-FU, etc.; Platinum compounds: carboplatin, cisplatin, oxaliplatin, lobeline, nedaplatin, cisplatin sodium chloride, oxaliplatin mannitol; Proteasome inhibitors: bortezomib, asparaginase, retinoic acid, acridine, estradiol, glycyrrhizin sodium, hexamethylmelamine, arsenite (arsenic trioxide), sodium arsenite oxide, ixazomib citrate capsules, pegaspargase injection, olaparib tablets, eribulin mesylate injection, nitrogen mustard, cyclophosphamide, cyclophosphamide injection, chlorambucil, melphalan, nicarfen, ifosfamide, bendamocin, semustine, formustine, carboplatin, etc. Mustin, lomustine, nimustine, thiotepa, dacarbazine, temozolomide, temozolomide for injection, thiotepa, dacarbazine, temozolomide for injection, etoposide, vinorelbine, topotecan, docetaxel albumin-bound, cabazitaxel; Antimetabolites: These drugs compete with enzymes for the binding of nucleic acid metabolites, affecting and blocking nucleic acid synthesis, such as fluorouracil, methotrexate, mercaptopurine, cytarabine, hydroxyurea, capecitabine, tegafur, cyclophosphamide, etc.; Antibiotics: Antitumor antibiotics such as mitomycin, doxorubicin, bleomycin, etc.; Alkaloids: Vincristine alkaloids mainly interfere with the formation of the intracellular spindle, causing the cell to arrest in metaphase of mitosis. Other drugs include hydroxycamptothecin, paclitaxel, and paclitaxel oral solution; etoposide; hormones and anti-hormones: these can alter the internal environment and thus affect tumor growth, and some can enhance the body's resistance to tumor invasion. Commonly used ones include tamoxifen, toremifene, anti-tumor drugs, diethylstilbestrol, progesterone, testosterone propionate, thyroxine, and prednisone; molecularly targeted drugs: targets can be cell receptors, signal transduction, and anti-angiogenesis; commonly used monoclonal antibodies include Herceptin, Rituxan, Cetuximab, and Bevacizumab; commonly used small molecule compounds include imatinib, gefitinib, larotrectinib, and tazex.

[0173] This application does not specifically limit the composition, which can be: injectable structured lipid chemotherapy drug, oral chemotherapy drug emulsion, oral chemotherapy drug, or soft capsule chemotherapy drug.

[0174] Chemotherapy drugs and Haematococcus pluvialis are added to the structural lipids to prepare soft capsules. The gelatin used includes: bone glue, which is mainly divided into pig bone glue, bovine bone glue, plant glue, fish scale glue, gelatin, sorbitol solution, glycerin, and water, which are the conventional ingredients for preparing soft capsules.

[0175] Structured lipids and medium- and long-chain fatty acids, such as structured triglycerides (emulsions, providing energy and reducing muscle loss) such as ZL201811316699.7, are homogenized in an appropriate ratio. This mixture is then homogenized with chemotherapy drug powders of different orientations required for cancer chemotherapy to obtain a composition. The composition is then homogenized with lecithin, glycerol, water, and sodium hydroxide to prepare an oral or injectable structured fat emulsion chemotherapy drug. Alternatively, the composition can be homogenized with a composite emulsifier to obtain an oral structured fat emulsion chemotherapy drug (i.e., an emulsion form). The composition can also be used to prepare other legally permitted enteral total nutrition emulsions.

[0176] When injectable structured triglyceride fat emulsion is diluted with chemotherapy drug injection, it can be prepared according to the following ingredients: structured triglyceride, refined lecithin, glycerin, water for injection, and sodium hydroxide (pH adjuster). For example, a 250ml specification contains 50g of refined structured triglyceride, 3g of refined lecithin, and 5.5g of anhydrous glycerin. The proportion of chemotherapy drug in the oil is 0.3-30%. Two 500ml specifications contain 100g of refined structured triglyceride and 6g of lecithin.

[0177] When used orally, the main ingredients of medium / long-chain triglycerides (MCTs) include soybean oil, medium-chain triglycerides (MCTs), long-chain triglycerides (LCTs), lecithin, water, and glycerin. In a 250ml container, the dosage is 2.5g soybean oil + 25g MCT, or 50g soybean oil + 50g MCT, 3g lecithin, and 5.5g anhydrous glycerin. Chemotherapy drugs comprise 0.3-30% of the fat content.

[0178] Oral structured fat emulsions C8-24 can be supplemented with emulsifiers such as compound emulsifier I, with 0.3-30% of chemotherapy drugs added. When the oral fat emulsion is C16-24, emulsifiers such as compound emulsifier II can be added. When used simultaneously with chemotherapy drugs recommended by the doctor, the patient can add an appropriate amount of water and shake to obtain a non-toxic chemotherapy fat emulsion.

[0179] In some examples of this application, the composition is further fortified with a nutrient fortifier, which includes Haematococcus pluvialis oil;

[0180] Optionally, the amount of Haematococcus pluvialis oil added is 1 to 3‰ of the weight of the structural lipid, for example, 1‰, 1.2‰, 1.4‰, 1.6‰, 1.8‰, 2‰, 2.2‰, 2.4‰, 2.6‰, 2.8‰, or 3‰.

[0181] Optionally, the weight ratio of the structural lipid to the chemotherapeutic drug is (96~100):(3~4), for example: 96:3, 96:3.5, 96:4, 98:3, 98:3.5, 98:4, 100:3, 100:3.5, 100:4.

[0182] In some examples of this application, the composition further includes an emulsifier; optionally, the amount of the emulsifier added is 2% to 4% of the weight of the structural lipid or the composition, for example, 2%, 2.2%, 2.4%, 2.6%, 2.8%, 3%, 3.2%, 3.4%, 3.6%, 3.8%, or 4%; optionally, the emulsifier includes one or more of the following: sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80), polyoxyethylene (20) sorbitan monooleate (Tween 80), polyoxyethylene (20) sorbitan monolaurate (Tween 20), mono- and diglycerides of fatty acids, polyglycerol fatty acids, polyethylene glycol fatty acids, and polyglycerol ricinoleate.

[0183] In some examples of this application, the composition also contains medium- to long-chain fatty acids;

[0184] Optionally, the method for preparing the medium- and long-chain fatty acids includes:

[0185] (a) Purified medium-chain fatty acid triglycerides and purified 14-24 C long-chain fatty acid triglycerides are added to a reactor, along with lipase and vitamin E as a catalyst. The transesterification reaction is carried out at a temperature of 40-85℃ (e.g., 40, 45, 50, 55, 60, 65, 70, 75, 80, 85℃) under a vacuum of 5-200 Pa (e.g., 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 Pa) for 15-34 h (e.g., 15, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 h), and the reaction is terminated to obtain material 1.

[0186] (b) The material 1 obtained in step (a) is purified at a temperature of 190~260℃ (e.g., 190, 200, 210, 220, 230, 240, 250, 260℃) with dry steam to remove acid, deodorize, remove medium chain residues and deactivate enzymes to obtain the target product, high-purity medium and long chain fatty acid oil.

[0187] Optionally, the weight ratio of the structural lipid or the composition to the medium- and long-chain fatty acid oil is (1~9):(1~4), such as 1:1, 1:2, 1:4, 6:1, 6:2, 6:4, 9:1, 9:2, 9:4.

[0188] The embodiments of this application will be described in detail below with reference to examples. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of this application. For experimental methods in the following embodiments where specific conditions are not specified, please refer to the guidelines given in this application, or follow experimental manuals or conventional conditions in the art, or follow the conditions recommended by the manufacturer, or refer to experimental methods known in the art.

[0189] In the specific embodiments described below, the measurement parameters involving raw material components may have slight deviations within the weighing accuracy range unless otherwise specified. Temperature and time parameters are subject to acceptable deviations due to instrument testing accuracy or operational precision.

[0190] Modified taurine immobilized lipase (propionyl laurate enzyme unit PLU / g 8000-14000): Purchased from Beijing Gaoruisen Technology Co., Ltd. in Examples 1 and 4, and from Weifang Kangdian Biotechnology Co., Ltd. in Examples 6 and 9.

[0191] Antarctic Candida lipase: Purchased from Beijing Gaoruisen Technology Co., Ltd. in Examples 2, 5, 8, 10, 11, and 13, and from Weifang Kangdian Biotechnology Co., Ltd. in Examples 3, 7, 12, 14, 15, and 16.

[0192] High-unsaturated fatty acid EE fish oil: Jiangsu Weisikang Food Technology Development Co., Ltd.

[0193] Refined fish oil: Hebei Kangruida Lipid Co., Ltd.

[0194] Compound emulsifier: Henan Zhengtong Food Technology Co., Ltd., model number: 306 or 408.

[0195] Example 1

[0196] 1. Mix 9 parts by weight of high-unsaturated fatty acid EE fish oil and 0.8 parts by weight to form oil 1. Add modified kojiase immobilized lipase, the amount of enzyme added is 3.5% of the weight of oil. React at 65℃, vacuum 200Pa for 24 hours, and then terminate the reaction to prepare fish oil extract, i.e., product 1.

[0197] 2. Mix 5.5 parts by weight of borage seed oil, 2.5 parts by weight of fish oil extract from step 1, 1 part by weight of *Sapindus mukorossi* oil, and 1 part by weight of pine nut oil to form oilseed 2. Add 4% by weight of modified *Aspergillus oryzae* immobilized lipase to oilseed 2. React at 65℃ and 150Pa vacuum for 24 hours. Deodorize and inactivate the enzyme by filtration steam at 175℃ for 2 hours. Cool to 65℃ to prepare product 2. Its composition is: 17.5% eicosapentaenoic acid (EPA) + 17.5% docosahexaenoic acid (DHA), 0.3% nervonic acid (C24:1), and 10.8% γ-linolenic acid.

[0198] 3. Product preparation

[0199] (1) Add Haematococcus pluvialis oil (astaxanthin oil) to product 2. The amount of Haematococcus pluvialis oil (astaxanthin oil) added is 1‰ of the weight of the product in step 2 to prepare product 3 (structural triglyceride).

[0200] (2) Product 3 is pressed into soft capsules with a net content of 0.85 grams using the prepared gelatin (gelatin, water, sorbitol solution, glycerin). The gelatin formula is: 145 mg gelatin, 45 mg glycerin, 45 mg sorbitol solution (sorbitol content greater than 90 wt%), and 12 mg water. It can be taken simultaneously with chemotherapy drugs.

[0201] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0202] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0203] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0204] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0205] Example 2

[0206] 1. Mix 9 parts by weight of high-unsaturated fatty acid EE fish oil and 0.75 parts by weight to form oil 1. Add immobilized lipase of Candida antarctica, the amount of enzyme added is 3.5% of the weight of oil. React at 65℃, vacuum 100Pa for 24 hours, and then terminate the reaction to prepare mixed glycerol ester reduced fish oil, i.e. product 1.

[0207] 2. Mix 4.5 parts by weight of the reduced fish oil from step 1, 4.0 parts by weight of borage seed oil, and 1.5 parts by weight of Acer truncatum seed oil to form oilseed 2. Add 4% by weight of Candida antarctica lipase to oilseed 2. React at 65℃ and 10Pa vacuum for 24 hours. Deodorize and inactivate the enzyme at 160℃. Filter to obtain product 2. Contains 99% fatty acids at the sn-2 position. Its composition is: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 31.5%, nervonic acid (C24:1) 0.4%, and γ-linolenic acid 7.2%.

[0208] 3. Product preparation

[0209] Product 2-1: Add Haematococcus pluvialis oil and cyclophosphamide powder to Product 2, homogenize, and compress with pre-made rubber (refer to the formula described in Example 1) to form soft capsules. The amount of Haematococcus pluvialis oil added is 1‰ of the weight of Product 2, and the amount of cyclophosphamide powder added is 3% of the weight of Product 2.

[0210] Product 2-2: Add 3% of compound emulsifier 408 to product 2 and homogenize it into a structured fat emulsion that emulsifies upon contact with water. The amount of compound emulsifier added is 3% of the weight of product 2. It is taken together with the chemotherapy drug cyclophosphamide.

[0211] Product 2-3: Product 2 was combined with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL201811316699.7) at a weight ratio of 3:2, and 3% cyclophosphamide powder was added and homogenized for 2 hours.

[0212] Product 2-4: Product 2 was homogenized with lecithin, glycerol, water, and sodium hydroxide to prepare an injectable fat emulsion.

[0213] Products 2-5: Enteral nutrition emulsions are prepared using product 2, wherein product 2 accounts for 14% of the weight of the enteral nutrition emulsion, and also satisfies the following:

[0214] Project NRV% per 100 grams (g)

[0215] Energy 3019 kJ 36%

[0216] Protein 18.8 grams (g) 31%

[0217] Fat 66.9 grams (g) 112%

[0218] Carbohydrates 13.2 grams (g) 4%

[0219] Sodium 32 mg 2%.

[0220] Soft capsules are used to alleviate the various symptoms caused by the toxic side effects of chemotherapy and improve the comfort of chemotherapy. This product in this example has a good inhibitory effect on hair loss during chemotherapy. It is suitable for use with cytotoxic drugs (alkylating agents).

[0221] Products 2-6: Haematococcus pluvialis oil was added to Product 2 and homogenized to prepare structured triglycerides. These were then compressed into soft capsules with a pre-made rubber sheet (refer to the formulation described in Example 1). The amount of Haematococcus pluvialis oil added was 1‰ of the weight of Product 2. This product can be taken concurrently with chemotherapy drugs.

[0222] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0223] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0224] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0225] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0226] Example 3

[0227] 1. Mix 9 parts by weight of highly unsaturated fatty acid EE fish oil and 1.1 parts by weight to form oil 1. Add IMNE0100 immobilized lipase, the amount of enzyme added is 4% of the weight of oil. React at 67℃, vacuum 200Pa for 24 hours, and then terminate the reaction to obtain mixed glycerol ester fish oil extract, i.e., product 1.

[0228] 2. Mix 3.5 parts by weight of fish oil extract from step 1, 5.5 parts by weight of borage seed oil, 0.6 parts by weight of *Sapindus mukorossi* oil, and 0.4 parts by weight of pine nut oil to form oil mixture 2. Add 4% by weight of IMNE100 immobilized lipase to oil mixture 2. React under vacuum of 50 Pa and temperature of 60°C for 25 hours, then inactivate the enzyme with steam at 175°C for 2 hours. Deodorize and cool to 60°C to obtain product 2. Its composition is: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 24.5%, nervonic acid (C24:1) 0.15%, and γ-linolenic acid 9.5%.

[0229] 3. Product preparation

[0230] Product 3-1: Add Haematococcus pluvialis oil (astaxanthin oil) to Product 2 and homogenize to prepare Product 3 (structural triglyceride). Compress with the prepared gelatin (refer to the formula described in Example 1) to form soft capsules. The amount of Haematococcus pluvialis oil (astaxanthin oil) added is 1‰ of the weight of Product 2. It can be taken concurrently with chemotherapy drugs.

[0231] Product 3-2: (1) Mix product 2 with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL201811316699.7) at a weight ratio of 2:1 and homogenize for 2 hours to obtain 97.9% of the sn-2 position fatty acid. Add the chemotherapy drug powder methotrexate, homogenize, and filter. (2) Mix the product of step (1) with lecithin, glycerol, and water and homogenize to obtain an injectable structured fat emulsion.

[0232] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0233] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0234] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0235] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0236] Example 4

[0237] 1. Mix 9 parts by weight of high-unsaturated fatty acid EE fish oil and 1.0 part by weight of glycerol to form oil 1. Add modified Aspergillus oryzae immobilized lipase. The amount of enzyme added is 4% of the weight of the oil. The reaction is carried out at a constant temperature of 67℃ and a vacuum of 100Pa for 24 hours. The reaction is then terminated to obtain the mixed glycerol ester reduced fish oil, i.e., product 1.

[0238] 2. Mix 4.0 parts by weight of reduced fish oil, 5.0 parts by weight of borage seed oil, and 1.0 part by weight of Acer truncatum seed oil to form oilseed 2. Add modified Aspergillus oryzae immobilized lipase at 3.5% of the weight of oilseed 2. React under vacuum of 10 Pa and at 65°C for 24 hours. Deodorize and inactivate the enzyme at 175°C, then filter to obtain a structured triglyceride, preparing product 2. Its composition is: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 28%, nervonic acid (C24:1) 0.3%, and γ-linolenic acid 9%.

[0239] 3. Product preparation

[0240] Product 4-1: Product 2 and the chemotherapy drug doxorubicin powder were homogenized at a weight ratio of 96.1:3.9. Haematococcus pluvialis oil (astaxanthin oil) was added at a weight of 1.3‰ of Product 2. The mixture was then pressed into soft capsules with a net weight of 0.85 grams using the prepared gelatin (refer to the formula described in Example 1 and replace the gelatin with fish scale glue).

[0241] Product 4-2: Product 2 and the chemotherapy drug doxorubicin powder were homogenized at a weight ratio of 96.1:3.9. The resulting homogenized product 1 was homogenized with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL201811316699.7) at a weight ratio of 3:2 under vacuum of 10 Pa and temperature of 67 °C to obtain 99.9% of the fatty acids at the sn-2 position, thus obtaining homogenized product 2. Egg yolk lecithin, water, and glycerol were added to homogenized product 2 under high pressure to prepare a non-toxic injectable chemotherapy drug structured fat emulsion.

[0242] Product 4-3: Haematococcus pluvialis oil was added to Product 2 and homogenized to prepare a structured triglyceride. This triglyceride was then compressed with a pre-made rubber sheet (refer to the formulation described in Example 1) to form soft capsules. The amount of Haematococcus pluvialis oil added was 1‰ of the weight of Product 2. It can be taken concurrently with chemotherapy drugs.

[0243] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0244] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0245] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0246] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0247] Example 5

[0248] 1. Mix 55 parts by weight of refined fish oil, 29 parts by weight of purified borage oil (with a gamma-linolenic acid content of 20%), 6 parts by weight of Acer truncatum seed oil, 10 parts by weight of pine nut oil (pinolenic acid), and 6 parts by weight of immobilized lipase 435 (i.e., the amount of enzyme used is 6% of the weight of the oil) in a sealed container, under vacuum conditions of 50 Pa, reaction temperature of 55 °C, and reaction time of 20 hours, and then terminate the reaction.

[0249] 2. The product is then subjected to a refining process. The reaction product is heated to approximately 120°C and mixed with dry steam at 160°C for flash evaporation. Distillation is then performed to deacidify, deodorize, and deactivate the enzymes. The product is then cooled and finely filtered to obtain polyunsaturated fatty acid structure lipids 1.

[0250] 3. Product preparation

[0251] Product 5-1: The product of step 2 and the prepared gelatin (refer to the formula described in Example 1 and replace the gelatin with bone glue) are pressed into soft capsules.

[0252] Product 5-2: (1) The product of step 2 is mixed with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL201811316699.7) at a weight ratio of 4:1 and homogenized for 2 hours to obtain 98.9% of the fatty acid at the sn-2 position. The product is then finely filtered to obtain the product. (2) The product obtained in step (2) is mixed with lecithin and glycerol and homogenized to obtain injectable structured fat. This product is mixed with etoposide diluent before injection.

[0253] Product 5-3: A structured triglyceride is prepared by homogenizing the addition of Haematococcus pluvialis oil to polyunsaturated fatty acid structured lipid 1, and then compressed into soft capsules with a pre-made rubber sheet (refer to the formula described in Example 1). The amount of Haematococcus pluvialis oil added is 1‰ of the weight of polyunsaturated fatty acid structured lipid 1. It can be taken concurrently with chemotherapy drugs.

[0254] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0255] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0256] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0257] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0258] Example 6

[0259] 1. 90 parts by weight of high-purity, highly unsaturated fatty acid ethyl ester fish oil (EPA+DHA accounting for 65%) and 13 parts by weight of glycerol were reacted in a reactor with 6% by weight of 435 lipase added. The reaction conditions were: vacuum 100 Pa, reaction temperature 70℃, and reaction time 20 hours. The reaction was terminated to obtain structured lipids containing 57% triglycerides, 29% diglycerides, and 15% monoglycerides. The final product 1 was obtained by fine filtration.

[0260] 2. Product preparation

[0261] Product 6-1: Product 1 is pressed into soft capsules with the prepared rubber sheet (refer to the formula described in Example 1).

[0262] Product 6-2: Product 1 was mixed and homogenized with medium- and long-chain fatty acid triglycerides (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 3:1. The fatty acid sn-2 position fatty acid content was measured to be 99%. After fine filtration, Product 2 was obtained. Product 2 was mixed and homogenized with lecithin, glycerol, and water to obtain an oral structured fat emulsion. When used, it was mixed with a diluted solution of the chemotherapy drug tamoxifen.

[0263] Product 6-3: Haematococcus pluvialis oil was added to Product 1 and homogenized to prepare a structured triglyceride. This triglyceride was then compressed with a pre-made rubber sheet (refer to the formulation described in Example 1) to form soft capsules. The amount of Haematococcus pluvialis oil added was 1‰ of the weight of Product 1. It can be taken concurrently with chemotherapy drugs.

[0264] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0265] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0266] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0267] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0268] Example 7

[0269] 1. Mix 50 parts borage seed oil, 35 parts fish oil, and 15 parts milk thistle seed oil. Add 3.5% (by weight of oil) of IMNE-100 immobilized lipase. The reaction temperature is 60℃, the reaction time is 26 hours, and the vacuum degree is 100Pa. The transesterification product is then subjected to high-temperature inactivation of the enzyme. The high-temperature inactivation reaction temperature is 195℃, the reaction time is 2 hours, and the vacuum degree is 120Pa to obtain polyunsaturated fatty acid structured lipids.

[0270] 2. Product preparation

[0271] Product 7-1: Product 1 was prepared by adding Haematococcus pluvialis oil to polyunsaturated fatty acid structured lipids. The amount of Haematococcus pluvialis oil added was 1‰ of the weight of the polyunsaturated fatty acid structured lipids. Product 1 was mixed and homogenized with compound emulsifier 408 to obtain an oral structured fat emulsion. The amount of compound emulsifier added was 3% of the weight of Product 1.

[0272] Product 7-2: Product 1 was mixed and homogenized with a medium- and long-chain fatty acid triglyceride (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 4:1 to obtain 98.5% of the fatty acid at the sn-2 position. The mixture was then filtered to obtain Product 2. Product 2 was mixed and homogenized with lecithin and glycerol to obtain an injectable structured fat emulsion. Before injection, the emulsion was diluted and mixed with the chemotherapy drug imatinib.

[0273] Product 7-3: Homogenized triglycerides are prepared by adding Haematococcus pluvialis oil to polyunsaturated fatty acid structured lipids, and then compressed into soft capsules with a pre-made rubber sheet (refer to the formula described in Example 1). The amount of Haematococcus pluvialis oil added is 1‰ of the weight of the polyunsaturated fatty acid structured lipids. It can be taken concurrently with chemotherapy drugs.

[0274] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0275] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0276] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart. In an antitumor model, this sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0277] Example 8

[0278] 1. Mix 9.5 parts of highly unsaturated fatty acid EE fish oil and 1.2 parts of glycerol by weight to form oil 1. Add Candida antarcticis immobilized lipase, the amount of enzyme is 4% of the weight of oil 1. React at 68℃ and 100Pa vacuum for 25 hours to obtain a mixed glycerol ester (triglyceride, diglyceride and monoglyceride) fish oil extract, i.e., product 1.

[0279] 2. Mix 3.8 parts by weight of fish oil extract, 5.2 parts by weight of borage seed oil, 0.5 parts by weight of *Sapindus mukorossi* oil, and 0.5 parts by weight of pine nut oil to form oilseed 2. Add *Candida antarctica* immobilized lipase at 3.5% of the weight of oilseed 2. React under vacuum (10 Pa) at 60°C for 26 hours, followed by steaming at 175°C for 2 hours to deodorize and inactivate the enzyme. Cool to 65°C to prepare product 2. Its composition is: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 26.6%, nervonic acid (C24:1) 0.15%, and γ-linolenic acid 9.3%.

[0280] 3. Product preparation

[0281] Product 8-1: Haematococcus pluvialis oil is added to Product 2. The amount of Haematococcus pluvialis oil added is 1‰ of the weight of Product 2. After fine filtration, Product 3 (structural triglyceride) is obtained. It is then pressed into soft capsules with the prepared rubber sheet (refer to the formula described in Example 1) and can be taken at the same time as chemotherapy drugs such as clofazimine.

[0282] Product 8-2: Product 3 was mixed and homogenized with a medium- and long-chain fatty acid triglyceride (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 3.5:1 to obtain 99.5% of the fatty acid at the sn-2 position. The mixture was then filtered to obtain Product 4. Product 4 was mixed and homogenized with lecithin, glycerol, and water to obtain an injectable structured fat emulsion. Before injection, the chemotherapy drug clofazimine was added.

[0283] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0284] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0285] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0286] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0287] Example 9

[0288] 1. Mix 10 parts of highly unsaturated fatty acid EE fish oil and 0.9 parts of glycerol by weight to form oil 1. Add modified rice enzyme immobilized lipase. The amount of enzyme added is 3.5% of the weight of the oil. React at 67°C and vacuum 150Pa for 24 hours. Then terminate the reaction to obtain fish oil extract, i.e., product 1.

[0289] 2. Mix 5.5 parts borage seed oil, 2.5 parts fish oil extract, 1 part *Sapindus mukorossi* oil, and 1 part pine nut oil by weight to form oilseed 2. Add modified *Aspergillus oryzae* immobilized lipase at 4% of the weight of oilseed 2. React at 65℃ and 150Pa vacuum for 24 hours. Deodorize and inactivate the enzyme by filtration steam at 175℃ for 2 hours. Cool to 65℃ to obtain the product structure: triglyceride fat, denoted as product 2. Its composition: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 17.5%, nervonic acid (C24) 10.3%, and γ-linolenic acid 9.9%.

[0290] 3. Product preparation

[0291] Product 9-1: Add Haematococcus pluvialis oil (astaxanthin oil) to Product 2 at a rate of 1‰ of the weight of Product 2 to prepare Product 3 (structural triglyceride). Compress Product 3 with the prepared gelatin (refer to the formula described in Example 1, but replace gelatin with bone glue) into soft capsules with a net weight of 0.85 grams. The fatty acid content at the sn-2 position was found to be 97%. It can be taken concurrently with chemotherapy drugs.

[0292] Product 9-2: Mix 100 parts of product 2, 12 parts of lecithin, 25 parts of glycerin, and an appropriate amount of sodium hydroxide water by weight, and homogenize under high pressure to form an emulsion. Dilute water-soluble cyclophosphamide according to the designed dosage and inject it into the emulsion for injection, nasogastric feeding, or tube feeding.

[0293] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0294] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0295] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0296] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0297] Example 10

[0298] 1. Mix 9 parts of highly unsaturated fatty acid EE fish oil and 1.1 parts of glycerol by weight to form oil 1. Add IMNE0100 immobilized lipase. The amount of enzyme added is 4% of the weight of oil 1. React at 67°C and 50 Pa under vacuum for 24 hours. Terminate the reaction to obtain mixed glycerol ester fish oil extract, which is denoted as product 1.

[0299] 2. Mix 3.5 parts by weight of fish oil extract, 5.5 parts of borage seed oil, 0.6 parts of *Sapindus mukorossi* oil, and 0.4 parts of pine nut oil to form oilseed 2. Add 4% by weight of IMNE100 immobilized lipase to oilseed 2. React under vacuum of 50 Pa and temperature of 60℃ for 25 hours. Inactivate the enzyme with steam at 175℃ for 2 hours. Deodorize and cool to 60℃, then filter to prepare product 2. Its composition is: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 24.5%, nervonic acid (C24:1) 0.18%, and γ-linolenic acid 9.9%.

[0300] 3. Product preparation

[0301] Product 10-1: Mix Product 2 with the chemotherapy drug cisplatin at a weight ratio of 96:4 and homogenize to obtain Product 3; add 1‰ of the weight of Product 2 Haematococcus pluvialis oil (astaxanthin oil) to Product 3, homogenize, and compress with the prepared rubber sheet (refer to the formula described in Example 1) to form a soft capsule chemotherapy drug.

[0302] Product 10-2: Mix product 3 with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 2:1 and homogenize for 2 hours to obtain 97.9% of the fatty acid at the sn-2 position. Homogenize and filter to obtain product 4. Mix product 4 with lecithin, glycerol and water and homogenize to obtain an injectable structured fat emulsion.

[0303] Product 10-3: Homogenize product 4 with compound emulsifier 306 (addition amount is 3% of the weight of product 4) to obtain a (water-emulsifying) structured fat emulsion, which can be injected, taken orally, fed through a nasogastric tube, or administered as a non-toxic chemotherapy drug during chemotherapy and targeted therapy in the process of home health care.

[0304] Product 10-4: Haematococcus pluvialis oil is added to Product 2 at a rate of 1‰ of the weight of Product 2. After fine filtration, Product 3 (structural triglyceride) is obtained and compressed into soft capsules with the prepared gel (refer to the formula described in Example 1). It can be taken concurrently with chemotherapy drugs.

[0305] Under the experimental conditions, the detoxifying and enhancing chemotherapy drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and enhancing chemotherapy drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapy (drug) structure lipids had anti-hair loss effects, specifically by increasing blood flow velocity in zebrafish.

[0306] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0307] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0308] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0309] Example 11

[0310] 1. Mix 8.8 parts by weight of highly unsaturated fatty acid EE fish oil and 1.2 parts by weight of glycerol to form oil 1. Add 4% by weight of IMNE0100 immobilized lipase to oil 1. React at 65°C and 100 Pa under vacuum for 25 hours. Terminate the reaction to obtain a mixed glycerol ester fish oil extract, denoted as product 1.

[0311] 2. Mix 3.4 parts by weight of fish oil extract, 5.6 parts of borage seed oil, 0.6 parts of *Sapindus mukorossi* oil, and 0.4 parts of pine nut oil to form oilseed 2. Add 4% by weight of IMNE100 immobilized lipase to oilseed 2 and react under vacuum of 50 Pa and temperature of 60℃ for 25 hours. Inactivate the enzyme with steam at 155℃ for 2 hours, deodorize, cool to 50℃, and finely filter to prepare product 2. Its composition is: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 23.8%, nervonic acid (C24:1) 0.18%, and γ-linolenic acid 10.0%.

[0312] 3. Product preparation

[0313] Product 11-1: Product 2 is mixed and homogenized with the chemotherapy drug cyclophosphamide at a weight ratio of 96:4 to obtain Product 3; Haematococcus pluvialis oil (astaxanthin oil) at 1‰ of the weight of Product 3 is added to Product 3 and homogenized, and then compressed with the prepared rubber sheet (refer to the formula in Example 1) to form a soft capsule chemotherapy drug.

[0314] Product 11-2: Product 3 is mixed and homogenized with 3% by weight of compound emulsifier 408 to prepare an oral structured fat emulsion (which becomes an emulsion upon contact with water).

[0315] Product 11-3: Product 3 was mixed with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 2:1 and homogenized for 2 hours to obtain 97.9% of the fatty acid at the sn-2 position. After homogenization and fine filtration, Product 4 was obtained. It can be administered orally, via nasogastric tube, or via tube feeding.

[0316] Product 11-4: Mix Product 4 with lecithin, glycerin, and water, homogenize, and administer by injection, oral administration, nasogastric feeding, or tube feeding.

[0317] Product 11-5: Haematococcus pluvialis oil is added to Product 2 at a rate of 1‰ of the weight of Product 2. After fine filtration, Product 3 (structural triglyceride) is obtained and compressed into soft capsules with the prepared gel (refer to the formula described in Example 1). It can be taken concurrently with chemotherapy drugs.

[0318] It is used as a non-toxic chemotherapy drug during home-based health care and chemotherapy and targeted therapy.

[0319] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0320] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0321] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0322] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0323] Example 12

[0324] 1. Mix 9.1 parts of highly unsaturated fatty acid EE fish oil and 0.9 parts of glycerol by weight to form oil 1. Add 4% by weight of IMNE0100 immobilized lipase to oil 1. React at 65℃ and vacuum 80Pa for 24 hours. Terminate the reaction to obtain a mixed glycerol ester fish oil extract, denoted as product 1.

[0325] 2. Mix 3.8 parts by weight of fish oil extract, 5.7 parts of borage seed oil, 0.2 parts of *Sapindus mukorossi* oil, 0.2 parts of pine nut oil, and 0.1 parts of almond oil to form oil mixture 2. Add 4% by weight of IMNE100 immobilized lipase to oil mixture 2. React under vacuum of 50 Pa and at 60°C for 25 hours. Inactivate the enzyme with steam at 175°C for 2 hours. Deodorize and cool to 60°C, then filter to obtain product 2. Its composition is: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 26.6%, nervonic acid (C24:1) 0.06%, and γ-linolenic acid 10.2%.

[0326] 3. Product preparation

[0327] Product 12-1: Product 2 and the chemotherapy drug cyclophosphamide are mixed and homogenized at a weight ratio of 96:4 to obtain Product 3; 1‰ of the weight of Haematococcus pluvialis oil (astaxanthin oil) of Product 2 is added to Product 3 and homogenized, and then pressed into soft capsules with the prepared gel (refer to the formula described in Example 1).

[0328] Product 12-2: Product 3 is mixed and homogenized with compound emulsifier 408 (3% of the weight of product 3) to prepare an oral structured fat emulsion (which becomes an emulsion upon contact with water).

[0329] Product 12-3: Product 3 was mixed with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 2:1 and homogenized for 2 hours to obtain 97.9% of the fatty acid at the sn-2 position. After homogenization and fine filtration, Product 4 was obtained and administered orally, via nasogastric tube, or via tube feeding.

[0330] Product 12-4: Mix product 4 with lecithin, glycerol and water and homogenize to obtain an injectable fat emulsion, which can be administered by injection, oral administration, nasogastric feeding or tube feeding.

[0331] Product 12-5: Haematococcus pluvialis oil is added to Product 2 at a rate of 1‰ of the weight of Product 2. After fine filtration, Product 3 (structural triglyceride) is obtained and compressed into soft capsules with the prepared gelatin (refer to the formula described in Example 1). It can be taken concurrently with chemotherapy drugs.

[0332] It is used as a non-toxic chemotherapy drug during home-based health care and chemotherapy and targeted therapy.

[0333] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0334] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0335] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0336] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0337] Example 13

[0338] 1. Mix 18 parts by weight of highly unsaturated fatty acid EE fish oil and 2 parts by weight of glycerol to form oil 1. Add 4% by weight of IMNE0100 immobilized lipase to oil 1. React at 65°C and 70 Pa under vacuum for 24 hours. Terminate the reaction to obtain a mixed glycerol ester fish oil extract, denoted as product 1.

[0339] 2. Mix 4.2 parts by weight of fish oil extract, 5.1 parts of borage seed oil, 0.5 parts of *Sapindus mukorossi* oil, and 0.2 parts of pine nut oil to form oilseed 2. Add 4% by weight of IMNE100 immobilized lipase to oilseed 2. React under vacuum at 50 Pa and 65°C for 25 hours to separate fatty acids. Inactivate the enzyme with steam at 175°C for 2 hours, cool to 60°C, and finely filter to obtain product 2. Its composition is: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 29%, nervonic acid (C24:1) 0.15%, and γ-linolenic acid 9.10%.

[0340] 3. Product preparation

[0341] Product 13-1: Add 1‰ of the weight of Haematococcus pluvialis oil (astaxanthin oil) to Product 2 and homogenize to prepare a structured triglyceride. Compress the triglyceride with the prepared gel (refer to the formula described in Example 1) to form soft capsules. It can be taken concurrently with chemotherapy drugs.

[0342] Product 13-2: Product 2 is mixed and homogenized with compound emulsifier 408 (the amount added is 3% of the weight of product 2) to prepare an oral structured fat emulsion (which becomes an emulsion upon contact with water).

[0343] Product 13-3: Product 2 was mixed with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 2:1 and homogenized for 2 hours to obtain 97.9% of the fatty acid at the sn-2 position. After homogenization and fine filtration, Product 3 was obtained. Product 3 was mixed with lecithin, glycerol and water and homogenized to obtain an injectable structured fat emulsion.

[0344] Product 13-4: Homogenize product 3 with compound emulsifier 306 (addition amount is 3% of the weight of product 3) to obtain a structured fat emulsion (emulsifies upon contact with water).

[0345] It can be used orally concurrently with chemotherapy and targeted therapy during home-based health care.

[0346] Animal experiment results: In zebrafish experiments, the number of neutrophils in the zebrafish heart was significantly reduced. The efficacy in improving sepsis was 54.05%, indicating a clear positive effect in alleviating sepsis-related inflammation.

[0347] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0348] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0349] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0350] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0351] Example 14

[0352] 1. Mix 15 parts of highly unsaturated fatty acid EE fish oil and 1.5 parts of glycerol by weight to form oil 1. Add 4% by weight of IMNE0100 immobilized lipase to oil 1. React at 65℃ and 90Pa vacuum for 24 hours. Terminate the reaction to obtain mixed glycerol ester fish oil extract, denoted as product 1.

[0353] 2. Mix 3.2 parts by weight of fish oil extract, 4.8 parts of borage seed oil, 1 part of *Sapindus mukorossi* oil, 0.6 parts of almond oil, and 0.4 parts of pine nut oil to form oil mixture 2. Add 4% by weight of IMNE100 immobilized lipase to oil mixture 2. React under vacuum of 50 Pa and temperature of 60℃ for 25 hours. Separate the immobilized enzyme, inactivate the enzyme by steaming at 175℃ for 2 hours, cool to 60℃, and finely filter to obtain product 2. Its composition is: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 22.3%, nervonic acid (C24:1) 0.3%, and γ-linolenic acid 8.5%.

[0354] 3. Product preparation

[0355] Product 14-1: Add 1‰ of the weight of Haematococcus pluvialis oil (astaxanthin oil) to Product 2 and homogenize to prepare a structured triglyceride. Compress the triglyceride with the prepared gel (refer to the formula described in Example 1) to form soft capsules (gel candies). It can be taken concurrently with chemotherapy drugs.

[0356] Product 14-2: Product 2 is mixed and homogenized with compound emulsifier 408 (the amount added is 3% of the weight of product 2) to prepare an oral structured fat emulsion (which becomes an emulsion when it comes into contact with water) to be taken simultaneously with oral chemotherapy drugs.

[0357] Product 14-3: Product 2 was mixed with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 2:1 and homogenized for 2 hours to obtain 97.9% of the fatty acid at the sn-2 position. Product 3 was obtained by fine filtration and the structured lipids were taken orally at the same time as the chemotherapy drugs.

[0358] Product 14-4: Mix and homogenize product 3 with lecithin, glycerol, and water to obtain an injectable fat emulsion. Inject the diluted chemotherapy drug into the fat emulsion and mix them together for use.

[0359] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0360] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0361] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0362] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0363] Example 15

[0364] 1. Mix 12 parts by weight of highly unsaturated fatty acid EE fish oil and 1.8 parts by weight of glycerol to form oil 1. Add 4% by weight of IMNE0100 immobilized lipase to oil 1. React at 65°C and 60 Pa under vacuum for 24 hours. Terminate the reaction to obtain mixed glycerol ester fish oil extract, which is denoted as product 1.

[0365] 2. Mix 3.7 parts by weight of fish oil extract, 5.4 parts of borage seed oil, 0.5 parts of *Sapindus mukorossi* oil, 0.2 parts of pine nut oil, and 0.2 parts of almond oil to form oil mixture 2. Add 4% by weight of IMNE100 immobilized lipase to oil mixture 2. React under vacuum of 50 Pa and at 60°C for 25 hours. Inactivate the enzyme with steam at 175°C for 2 hours. Deodorize and cool to 60°C, then filter to obtain product 2. Its composition: 25.5% eicosapentaenoic acid (EPA) + 25.5% docosahexaenoic acid (DHA), 0.15% nervonic acid (C24:1), and 9.7% γ-linolenic acid.

[0366] 3. Product preparation

[0367] Product 15-1: Product 2 and chemotherapy drug (5-FU fluorouracil) are mixed and homogenized at a weight ratio of 96:4 to obtain Product 3; 1‰ of the weight of Haematococcus pluvialis oil (astaxanthin oil) of Product 2 is added to Product 3 and homogenized, and the prepared gel (refer to the formula water described in Example 1) is pressed into soft capsules.

[0368] Product 15-2: Product 3 is mixed and homogenized with compound emulsifier 408 (the amount added is 3% of the weight of product 3) to prepare an oral structured fat emulsion (which becomes an emulsion when it comes into contact with water) for oral, nasogastric, or tube feeding.

[0369] Product 15-3: Product 3 was mixed with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 2:1 and homogenized for 2 hours to obtain 97.9% of the fatty acid at the sn-2 position. After homogenization and fine filtration, Product 4 was obtained. Product 4 was mixed with lecithin, glycerol and water and homogenized to obtain an injectable structured fat emulsion, which can be administered by injection, oral administration, nasogastric feeding or tube feeding.

[0370] Product 15-4: Haematococcus pluvialis oil is added to Product 2 at a rate of 1‰ of the weight of Product 2. After fine filtration, Product 3 (structural triglyceride) is obtained and compressed into soft capsules with the prepared gel (refer to the formula described in Example 1). It can be taken concurrently with chemotherapy drugs.

[0371] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0372] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0373] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0374] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0375] Example 16

[0376] 1. Mix 17 parts by weight of highly unsaturated fatty acid EE fish oil and 3 parts by weight of glycerol to form oil 1. Add 4% by weight of IMNE0100 immobilized lipase to oil 1. React at 65°C and 70 Pa under vacuum for 24 hours. Terminate the reaction to obtain a mixed glycerol ester fish oil extract, denoted as product 1.

[0377] 2. Mix 3.3 parts by weight of fish oil extract, 5.5 parts of borage seed oil, 0.4 parts of *Sapindus mukorossi* oil, 0.4 parts of pine nut oil, and 0.4 parts of almond oil to form oil 2. Add 4% by weight of IMNE100 immobilized lipase to oil 2. React under vacuum of 50 Pa and temperature of 60 °C for 25 hours. Inactivate the enzyme with steam at 175 °C for 2 hours. Deodorize and cool to 60 °C. Filter to obtain product 2.

[0378] Its composition includes: eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) 23.1%, nervonic acid (C24:1) 0.12%, and γ-linolenic acid 9.9%.

[0379] 3. Product preparation

[0380] Product 16-1: Product 2 and chemotherapy drug (paclitaxel) are mixed and homogenized at a weight ratio of 96:4 to obtain Product 3; 1‰ of the weight of Haematococcus pluvialis oil (astaxanthin oil) of Product 2 is added to Product 3 and homogenized, and then pressed into soft capsules using the prepared rubber sheet (refer to the formula described in Example 1).

[0381] Product 16-2: Product 3 is mixed and homogenized with compound emulsifier 408 (the amount added is 3% of product 3) to prepare an oral structured fat emulsion (which becomes an emulsion when it comes into contact with water) for oral, nasogastric, or tube feeding.

[0382] Product 16-3: Product 3 was mixed with medium- and long-chain fatty acids (the target product prepared in Example 3 of ZL20181136699.7) at a weight ratio of 2:1 and homogenized for 2 hours to obtain 97.9% of the sn-2 position fatty acid. After homogenization and fine filtration, Product 4 was obtained. Product 4 was mixed with lecithin, glycerol and water and homogenized to obtain an injectable structured fat emulsion, which can be administered by injection, oral administration, nasogastric feeding or tube feeding.

[0383] Product 16-4: Haematococcus pluvialis oil is added to Product 2 at a rate of 1‰ of the weight of Product 2. Product 3 is obtained by fine filtration and then compressed into soft capsules with the prepared gelatin (refer to the formula described in Example 1). It can be taken concurrently with chemotherapy drugs.

[0384] The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. The detoxifying and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipids have anti-hair loss effects, specifically manifested in increasing blood flow velocity in zebrafish.

[0385] In an immunodeficiency model, the sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac erythrocytes.

[0386] In a sepsis model, this sample significantly reduced the number of neutrophils in the zebrafish heart.

[0387] In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells and zebrafish lymphoma cells, respectively.

[0388] Comparative Example 1

[0389] By weight, 35 parts of polyene fish oil EE, 52 parts of borage seed oil, 9 parts of saxifrage oil and 4 parts of pine nut oil were mixed to form an oilseed. 4% of the oilseed weight of IMNE100 immobilized lipase was added. The mixture was reacted for 25 hours under vacuum of 50 Pa and temperature of 60 °C. The enzyme activity was then inactivated by steam at 175 °C for 2 hours. The mixture was deodorized and cooled to 60 °C. After fine filtration, the fatty acid content at the sn-2 position was found to be 65%.

[0390] The product provided in the above example was entrusted to Baihuan Biotechnology (Guangzhou) Co., Ltd. for efficacy verification experiments.

[0391] Experimental Project: Using a zebrafish model, this study evaluated the detoxifying and enhancing effects of a triglyceride (the soft capsule contents of product 12-5 in Example 12) as a chemotherapy drug carrier, improving white blood cell and red blood cell levels, preventing sepsis, preventing hair loss, and fighting tumors.

[0392] I. Detection Principle

[0393] Modeling Principle: The core principle of using zebrafish to detect the improvement effect of chemotherapy toxicity is to construct a damage model based on their highly homologous physiological mechanisms and visualization advantages with humans, accurately capturing the repair effect of interventions. With over 82% homology to human disease-related genes, and conserved functions and metabolic pathways in key organs such as the liver, heart, and hematopoietic system, zebrafish can highly simulate human clinical toxicity phenotypes in response to chemotherapy drugs such as cisplatin and doxorubicin. Utilizing the transparent nature of embryos and juvenile zebrafish, combined with transgenic technology (such as TG (lyz:dsred) zebrafish labeled with neutrophils) and microscopic observation, morphological abnormalities such as pericardial edema and myocardial fiber disorder, as well as blood toxicity characteristics such as changes in platelet and neutrophil counts, can be directly visualized. In experiments, a stable toxicity model is first constructed using standardized methods, then the target improvement agent is introduced. By comparing the toxic reactions of the intervention group and the control group, the protective effect and mechanism of action of the improvement agent can be rapidly quantified, providing efficient in vivo detection evidence for the screening of chemotherapy toxicity protective drugs.

[0394] The principle of immunodeficiency modeling: Cyclophosphamide is used to induce an immunodeficiency model in zebrafish. Cyclophosphamide is metabolized into the active product phosphoramide mustard, which can cross-link with DNA double strands, inhibiting DNA replication and transcription of immune cells. It can also activate the mitochondrial apoptosis pathway, inducing apoptosis of T cells, B cells, and macrophages, and inhibiting cytokine secretion, thereby weakening immune function. The zebrafish immune system is conserved compared to humans, possessing immune organs such as the thymus, kidneys, and spleen, as well as immune cells such as erythrocyte transport function, macrophages, T cells, and B cells. Furthermore, the zebrafish's transparent embryos, rapid reproduction, and suitability for high-throughput experiments make it an ideal modeling subject. After successful modeling, zebrafish exhibit typical characteristics of immunodeficiency, such as a reduced number of immune cells, decreased lymphocyte function, weakened inflammatory response, inhibition of erythrocyte production by drugs, and increased susceptibility to infection.

[0395] Principle of Sepsis Modeling: LPS-Induced Zebrafish Sepsis Model. The core principle of LPS (lipopolysaccharide)-induced zebrafish sepsis is to simulate a key pathogenic link in Gram-negative bacterial infection. As an "endotoxin" of the Gram-negative bacterial cell wall, LPS's core toxic lipid A can be recognized by the TLR4-MD2 receptor complex on the surface of zebrafish innate immune cells (such as macrophages). After receptor activation, downstream signaling pathways such as NF-κB are initiated through molecules like MyD88, triggering a massive release of inflammatory factors (such as IL-1β and TNF-α). These factors diffuse through the bloodstream, inducing a systemic, uncontrolled inflammatory response, leading to typical sepsis characteristics in zebrafish, such as abnormal activity, edema, organ damage, and even death. Furthermore, the immune signaling pathways in zebrafish and humans are highly conserved during this process, making the model suitable for studying the mechanism of sepsis and screening drugs.

[0396] The principle of anti-tumor modeling: A zebrafish tumor transplantation model is established by injecting fluorescently labeled tumor cells into zebrafish. This method allows for the transplantation of many tumor cell types into zebrafish, enabling the study of mechanisms of cancer cell differentiation, proliferation, and migration, as well as therapeutic applications. The optical transparency of juvenile zebrafish allows for direct observation of tumor proliferation, migration, and drug distribution. The degree of metastasis in juvenile zebrafish of many cancer cells, such as breast cancer, prostate cancer, and colon cancer, is directly proportional to their in vitro invasion potential, similar to results from in vitro or mouse experiments. Tumor occurrence and development are correlated with apoptosis and angiogenesis. Abnormalities in the apoptosis pathway play a crucial role in tumorigenesis; anti-tumor angiogenesis, cutting off the nutrient supply to tumor cells, is one of the important ways to inhibit tumor development. In recent years, zebrafish models have been increasingly used to screen drugs with apoptosis and anti-angiogenic activity. In clinical research, survival time is a rough estimate made by doctors based on a patient's condition and physical status; improving the survival time of cancer patients is of great significance in clinical research.

[0397] II. Technological Advantages

[0398] Zebrafish, as a research model for chemotherapy detoxification, have core advantages in the following five aspects:

[0399] 1) Gene homology, accurately simulating human response: It shows that zebrafish and humans have 87% genetic similarity, similar signal transduction and physiological structure, and their response to chemotherapy toxicity is close to that of humans. The experimental results have high reference value for human use.

[0400] 2) Physiological transparency allows for direct observation of toxic effects: This indicates that zebrafish embryos are transparent, allowing for direct observation of the effects of chemotherapy drugs on organs such as the blood system, thus facilitating research on toxicity mechanisms and drug efficacy.

[0401] 3) High reproductive efficiency and more statistically significant data: The introduction of zebrafish shows that they reproduce quickly and produce a large number of eggs each time, providing a large number of single experimental samples, which makes the experimental statistical analysis results highly reliable.

[0402] 4) Low cost, economical choice for scientific research: The analysis of zebrafish is based on their small size, low breeding cost, low drug dosage, and short experimental cycle, which reduces the cost of studying chemotherapy toxicity and screening drugs.

[0403] 5) Diverse drug administration: adapting to different drug characteristics: explaining that zebrafish can be administered drugs in multiple ways to adapt to different drug characteristics, providing a flexible experimental protocol for studying chemotherapeutic drugs and drugs that improve toxicity.

[0404] III. Materials and Methods

[0405] 3.1 Animal husbandry and handling

[0406] Adult zebrafish were housed in a recirculating aquaculture system at a maintained temperature of 28°C, with a photocycle of 14 hours of light / 10 hours of darkness, and were fed three times daily. To obtain embryos, sexually mature zebrafish were paired at a 1:1 female-to-male ratio at night and separated by a baffle. The baffle was removed within one hour of the start of the next photocycle to allow for natural spawning. The collected embryos were placed in a 1 × E3 solution (10 cm diameter petri dish) containing 0.3 ppm methylene blue and cultured in a 28.5°C artificial climate chamber (14 h / 10 h light / dark) until the experimental treatment stage.

[0407] 3.2 Instruments, Consumables and Reagents

[0408] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); Precision electronic balance (CP214, OHAUS, USA); Digital pneumatic microinjection pump (DMP-200, Wuhan Gairdna Technology Co., Ltd., China); Programmable vertical drawing instrument (PL-200, Wuhan Gairdna Technology Co., Ltd., China).

[0409] Cisplatin (batch number: L2419386, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Cyclophosphamide (batch number: K2425268, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Methotrexate (batch number: C17130216, Shanghai Maclean Biochemical Technology Co., Ltd., China); Clofazimine (batch number: K2411036, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Tamoxifen (batch number: B2527587, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Doxorubicin Hydrochloride (batch number: C17254653, Shanghai Maclean Biochemical Technology Co., Ltd., China); Imatinib (batch number: D2521035, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Etoposide ( Batch No.: C16775464, Shanghai Maclean Biotechnology Co., Ltd., China); 5-FU (Batch No.: H2512063, Shanghai Aladdin Biotechnology Co., Ltd., China); Paclitaxel (Batch No.: 2612021, Shanghai Aladdin Biotechnology Co., Ltd., China); Cyclophosphamide (Lot: K2425268, Shanghai Aladdin Biotechnology Co., Ltd., China); Lipopolysaccharide (LPS, Lot: AL8880, Shanghai Jizhi Biotechnology Co., Ltd., China).

[0410] 3.3 Exploration of Maximum Non-Lethal Concentration (MTC)

[0411] (1) Experimental grouping for reducing chemotherapeutic drug toxicity: normal control group, model control group, and sample group (chemotherapeutic drug carrier structure with detoxification and efficacy enhancement: triglycerides: 250, 500, 1000, 2000 and 4000 μg / mL; cisplatin: 400, 500, 600, 700 and 800 μM; cyclophosphamide: 1, 2, 4, 8, 16 and 32 mM; methotrexate: 25, 50, 100, 200, 400 and 800 μM; clofazimine: 2, 4, 8, 16, 32 and 64 μM; tamoxifen: 0.625, 1.25, 2.5, 5, 10 and 20 μM; doxorubicin hydrochloride: 25, 50, 100, 200, 400 and 800 μM; imatinib: 30, 60, 120, 240, 480 and 960 μM). μM; etoposide: 0.25, 0.5, 1, 2, 4 and 8 mM; paclitaxel: 25, 50, 100, 200 and 400 μM; 5-FU: 4, 8, 16, 32 and 64 μM).

[0412] Treatment method: Wild-type AB strains of zebrafish 2 days post-fertilization (2 dpf) were randomly selected. Tumor cells (see table below) were microinjected into the yolk sac of 2 dpf zebrafish. After injection, the fish were immediately rinsed three times in standard dilution water to ensure complete reactivation. All fish were then transferred to wide-mouthed tanks and treated for 24 h. At 13:00 on 3 dpf, zebrafish in good condition with uniform tumor cell size were randomly assigned to 6-well plates, 30 fish / well. The normal control group and the sample group (as shown in Table 1) were cultured normally. After 72 h, the drug solution was washed off, and the MTC of the samples for the model zebrafish was measured.

[0413]

[0414] (2) Experimental grouping for improving sepsis: normal control group, model control group, and triglyceride group with detoxification and enhanced efficacy of chemotherapy drug carrier structure (samples were set at 5 concentration gradients: 2000 μg / mL, 1000 μg / mL, 500 μg / mL, 250 μg / mL, 125 μg / mL).

[0415] Treatment method: Zebrafish 2 days post-fertilization (2 dpf) were randomly selected and enclosed in 6-well plates (3 mL / well), with 30 fish per well. Except for the normal control group, all other groups were administered cyclophosphamide in water to induce a zebrafish immunodeficiency model. The sample groups were simultaneously administered different concentrations of the sample in water. All groups were treated for 48 h, and the concentration at which no visible adverse reactions were observed was selected as the mean toxicity (MTC) of the sample.

[0416] (3) Experimental grouping for improving red blood cell levels after chemotherapy: normal control group, model control group, and triglyceride group with detoxification and enhanced efficacy of chemotherapy drug carrier structure (samples were set at 5 concentration gradients: 2000 μg / mL, 1000 μg / mL, 500 μg / mL, 250 μg / mL, 125 μg / mL).

[0417] Treatment method: Zebrafish 2 days post-fertilization (2 dpf) were randomly selected and enclosed in 6-well plates (3 mL / well), with 30 fish per well. Except for the normal control group, all other groups were given a cyclophosphamide-induced erythrocyte hypocytosis model in zebrafish, while the sample groups were simultaneously given different concentrations of the cyclophosphamide. All groups were treated for 48 h, and the concentration at which no visible adverse reactions were observed was selected as the mean toxicity (MTC) of the sample.

[0418] (4) Anti-tumor experimental groups: normal control group, model control group (200 myeloid tumor cells HL-60), and triglyceride group with detoxification and efficacy enhancement of chemotherapy drug carrier structure (5 concentration gradients: 2000 μg / mL, 1000 μg / mL, 500 μg / mL, 250 μg / mL, 125 μg / mL, a total of 6 groups).

[0419] Treatment method: Healthy zebrafish of uniform fertilization, 2 days post-fertilization (2 dpf), were randomly selected for the experiment in 6-well plates (3 mL / well), with 30 fish per well. The model control group and the triglyceride group (containing a detoxifying and enhancing chemotherapy drug carrier structure) were each injected with 200 HL-60 myeloid tumor cells. After 24 h of incubation, the triglyceride group was treated with different concentrations of the detoxifying and enhancing chemotherapy drug carrier structure solution. After 48 h of treatment, the mortality rate of each well was recorded.

[0420] 3.4 Evaluation of the detoxification efficacy of triglyceride-based chemotherapy drug carrier structures and their detoxification-enhancing effects

[0421] Experimental groups: normal control group, anticancer drug group (cisplatin: 600 μM; cyclophosphamide: 8 mM; methotrexate: 800 μM; clofazimine: 24 μM; tamoxifen: 10 μM; doxorubicin hydrochloride: 100 μM; imatinib: 60 μM; etoposide: 8 mM; paclitaxel: 400 μM; 5-FU: 32 mM), and combination of detoxifying and enhancing chemotherapy drug carrier triglyceride and anticancer drugs (detoxifying and enhancing chemotherapy drug carrier triglyceride: 250, 500 and 1000 μg / mL).

[0422] Treatment method: Wild-type AB strain zebrafish 2 days post-fertilization (2 dpf) were randomly selected. Tumor cells were microinjected into the yolk sac of the 2 dpf zebrafish. After injection, the fish were immediately rinsed three times in standard dilution water to ensure complete reactivation. Then, all fish were transferred to wide-mouthed tanks and treated at 35 ℃ for 24 h. At 13:00 on the 3 dpf day, zebrafish in good condition with uniform tumor cell size were randomly assigned to 6-well plates, 30 fish / well. The normal control group and the sample group (as shown in Table 2) were cultured normally. After 72 h, the drug solution was washed off, and the toxicity of the zebrafish was observed.

[0423] 3.5 Improves white blood cell levels (neutrophils) after chemotherapy

[0424] Experimental groups: normal control group, model control group, and sample group (sample concentration: 1000 μg / mL).

[0425] Treatment method: Two-day-free (dpf) zebrafish were randomly selected and placed in 6-well plates (3 mL / well), with 30 fish per well. Except for the normal control group, all other groups were treated with cyclophosphamide to induce a zebrafish immunodeficiency model. Samples were administered in water. Both normal control and model groups were set up, and all groups were treated for 48 h. Ten zebrafish from each experimental group were randomly selected and photographed under a microscope. The number of neutrophils in the tail vein was counted to evaluate the efficacy of the sample in improving white blood cell levels after chemotherapy.

[0426]

[0427] 3.6 Improves white blood cell (T cell) levels after chemotherapy

[0428] Experimental groups: normal control group, model control group, and sample group (sample concentration: 1000 μg / mL).

[0429] Treatment method: 2-day-flood (dpf) zebrafish were randomly selected and placed in 6-well plates (3 mL / well), with 30 fish per well. Except for the normal control group, all other groups were treated with cyclophosphamide to induce a zebrafish immunodeficiency model, with samples administered in water. Both normal and model groups were included, and all groups were treated for 48 h. Ten zebrafish from each experimental group were randomly selected and photographed under a microscope. The fluorescence intensity (pixels) of thymic T cells in the zebrafish was counted to evaluate the efficacy of the samples in improving white blood cell levels after chemotherapy.

[0430]

[0431] 3.7 Improves white blood cell levels (macrophages) after chemotherapy

[0432] Experimental groups: normal control group, model control group, and sample group (sample concentration: 1000 μg / mL).

[0433] Treatment method: Two-day-free (dpf) zebrafish were randomly selected and placed in 6-well plates (3 mL / well), with 30 fish per well. Except for the normal control group, all other groups were treated with cyclophosphamide to induce a zebrafish immunodeficiency model. Samples were administered via water-soluble cyclophosphamide. Both normal and model groups were included, and all groups were treated for 48 h. Ten zebrafish from each experimental group were randomly selected and photographed under a microscope. The number of macrophages in the zebrafish tail vein was counted to evaluate the efficacy of the sample in improving white blood cell levels after chemotherapy.

[0434]

[0435] 3.8 Improves red blood cell levels after chemotherapy

[0436] Experimental groups: normal control group, model control group, and triglyceride group with detoxification and efficacy enhancement of chemotherapy drug carrier structure (sample concentration: 1000 μg / mL).

[0437] Treatment method: 2-day-flood (dpf) zebrafish were randomly selected and placed in 6-well plates (3 mL / well), with 30 fish per well. Except for the normal control group, all other groups were treated with cyclophosphamide to induce a zebrafish erythrocyte hypocytosis model. Samples were administered via water-soluble cyclophosphamide. Both normal and model groups were included, and all groups were treated for 48 h. Ten zebrafish from each experimental group were randomly selected and photographed under a microscope. The number and staining intensity of cardiac cells were counted to evaluate the efficacy of the samples in improving erythrocyte levels after chemotherapy.

[0438]

[0439] 3.9 Improves sepsis

[0440] Experimental groups: normal control group, model control group, and sample group (sample concentration: 1000 μg / mL).

[0441] Treatment method: 30 zebrafish with a 3-day pf (dpf) growth rate were randomly selected and placed in 6-well plates (3 mL / well). The sample groups were pretreated with water-soluble solutions for 1 h. After treatment, except for the normal control group, each fish in the other groups received an injection of 10.0 nL LPS into the heart. Treatment continued for 2 h after injection. After treatment, 10 zebrafish from each experimental group were randomly selected and imaged under a microscope. The efficacy of the samples in improving sepsis was evaluated by counting the number of neutrophils in the zebrafish's heart.

[0442]

[0443] 3.10 Preventing Hair Loss

[0444] Experimental groups: normal control group, model control group, and sample group (samples were set at one concentration: 1000, 500, and 250 μg / mL).

[0445] Treatment method: 3-day-first-release (dpf) zebrafish were randomly selected and placed in 6-well plates (3 mL / well). Tumor cells were microinjected into the yolk sac of 2-day-first-release (dpf) zebrafish. After injection, the fish were immediately rinsed three times in standard dilution water to ensure complete reactivation. All fish were then transferred to wide-mouthed tanks and treated for 24 hours. At 13:00 on the 3-day-first-release (dpf) group, zebrafish in good condition with uniform tumor cell size were randomly assigned to 6-well plates (30 fish / well). The normal control group and the samples were cultured with cisplatin as usual. After 24 hours, the drug solution was washed off. After treatment, 10 zebrafish from each experimental group were randomly selected and placed in a blood flow analyzer to observe the overall blood flow velocity, thereby evaluating the anti-hair loss efficacy of the samples.

[0446] 3.11 Anti-tumor activity (HL-60 myeloid tumor cells)

[0447] Experimental groups: model control group (200 myeloid tumor cells HL-60), and triglyceride group with detoxification and efficacy enhancement of chemotherapy drug carrier structure (concentration: 2000 μg / mL).

[0448] Methods: Healthy zebrafish, 2 days post-fertilization (2 dpf) with consistent fertilization status, were randomly selected for the experiment in 6-well plates (3 mL / well), with 30 fish per well. Both the model control group and the triglyceride group (containing a detoxifying and enhancing chemotherapeutic drug carrier structure) were injected with 200 HL-60 myeloid tumor cells to establish a tumor model. After 24 h of incubation, the triglyceride group was treated with the detoxifying and enhancing chemotherapeutic drug carrier structure solution. After 48 h of treatment, images were captured under a fluorescence microscope, and the antitumor efficacy of the detoxifying and enhancing chemotherapeutic drug carrier structure was evaluated by statistically analyzing the fluorescence intensity of the zebrafish myeloid tumor cells.

[0449]

[0450] 3.12 Anti-tumor (lymphoma cell jurachatin)

[0451] Experimental groups: model control group (200 jurkat lymphoma cells) and triglyceride group with detoxification and efficacy enhancement of chemotherapy drug carrier structure (concentration: 2000 μg / mL).

[0452] Methods: Healthy zebrafish of uniform fertilization, 2 days post-fertilization (2 dpf), were randomly selected for the experiment in 6-well plates (3 mL / well), with 30 fish per well. Both the model control group and the triglyceride group (containing a detoxifying and enhancing chemotherapeutic drug carrier structure) were injected with 200 Juramat lymphoma cells to establish a tumor model. After 24 h of incubation, the triglyceride group was treated with the detoxifying and enhancing chemotherapeutic drug carrier structure solution. After 48 h of treatment, images were captured under a fluorescence microscope, and the antitumor efficacy of the detoxifying and enhancing chemotherapeutic drug carrier structure was evaluated by statistically analyzing the fluorescence intensity of the zebrafish lymphoma cells.

[0453]

[0454] 3.13 Statistical Analysis

[0455] Data analysis was performed using GraphPad Prism 8.0 statistical software. Quantitative data are expressed as mean ± standard error (mean ± SEM). Independent samples t-tests were used for comparisons between groups. p < 0.05 was considered statistically significant.

[0456] IV. Experimental Results

[0457] 4.1 MTC Exploration

[0458] (1) Experiment on reducing the toxicity of chemotherapy drugs

[0459] Under the experimental conditions, the maximum detectable concentration (MTC) of triglycerides, the chemotherapeutic drug carrier structure that enhances detoxification and efficacy in the samples, was 1000 μg / mL; the detectable concentration of cisplatin was 600 μM; the zebrafish toxicity concentration of cyclophosphamide was 8 mM; the zebrafish toxicity concentration of methotrexate was 800 μM; the zebrafish toxicity concentration of clofazimine was between 16-32 μM; the zebrafish toxicity concentration of tamoxifen was 10 μM; the zebrafish toxicity concentration of doxorubicin hydrochloride was 100 μM; the zebrafish toxicity concentration of imatinib was 60 μM; the zebrafish toxicity concentration of etoposide was 8 mM; the zebrafish toxicity concentration of paclitaxel was 400 μM; and the zebrafish toxicity concentration of 5-FU was 32 mM. See Table 1.1 for details.

[0460] Table 1.1 Results of the exploratory experiment on sample toxicity concentration (n = 30)

[0461]

[0462] (2) Improve white blood cell levels after chemotherapy

[0463] Under the experimental conditions, after 48 h of exposure to zebrafish, the triglyceride structure of the chemotherapy drug carrier for detoxification and enhancement in the sample resulted in abnormal mortality at a treatment concentration of 2000 μg / mL. The phenotypes at other treatment concentrations were similar to those in the model control group. Therefore, the MTC of the triglyceride structure of the chemotherapy drug carrier for detoxification and enhancement in zebrafish can be determined to be 1000 μg / mL. See Table 1.2 for details.

[0464] Table 1.2 Results of the experiment on the detoxification and enhancement of chemotherapy drug carrier structure by triglycerides and their effect on improving white blood cell concentration after chemotherapy (n = 30)

[0465]

[0466] (3) Improve red blood cell levels after chemotherapy

[0467] Through exposure treatment of zebrafish, the triglyceride structure of the chemotherapy drug carrier with detoxification and enhancement in the sample resulted in abnormal mortality at a treatment concentration of 2000 μg / mL, while the phenotypes at other treatment concentrations were similar to those in the model control group. Therefore, the MTC of the triglyceride structure of the chemotherapy drug carrier with detoxification and enhancement in the sample for zebrafish can be determined to be 1000 μg / mL. See Table 1.3 for details.

[0468] Table 1.3 Results of the experiment on the detoxification and enhancement of chemotherapy drug carrier structure by triglycerides and their effect on improving red blood cell concentration after chemotherapy (n = 30)

[0469]

[0470] (4) Anti-tumor

[0471] After 48 hours of exposure to zebrafish, the detoxification-enhancing chemotherapeutic drug carrier triglyceride at concentrations of 2000 μg / mL and below showed similar behavior to the model control group. Therefore, the MTC of the detoxification-enhancing chemotherapeutic drug carrier triglyceride in zebrafish can be determined to be 2000 μg / mL. See Table 1.4 for details.

[0472] Table 1.4 Results of the experiment on the antitumor (myeloid) concentration of triglycerides in chemotherapy drug carriers that enhance detoxification and efficacy (n = 30)

[0473]

[0474] 4.2 Evaluation of the detoxification efficacy of triglyceride-based chemotherapy drug carrier structures that enhance detoxification and efficacy.

[0475] 4.2.1 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Effects in Alleviating Cisplatin Toxicity

[0476] Under the experimental conditions, the mortality rate of zebrafish in the cisplatin 600 μM group was 43%, the deformity rate was 57%, and the average heart rate was 39.6 beats / 20 s; the mortality rate of zebrafish in the group with a 250 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 600 μM cisplatin was 0%, the deformity rate was 3%, and the average heart rate was 42.5 beats / 20 s; the mortality rate of zebrafish in the group with a 500 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 600 μM cisplatin was 3%, the deformity rate was 3%, and the average heart rate was 42.6 beats / 20 s; the mortality rate of zebrafish in the group with a 1000 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 600 μM cisplatin was 0%, the deformity rate was 3%, and the average heart rate was 42.4 beats / 20 s. s; indicating that the detoxification and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides can help improve the cancer chemotherapy of cisplatin, specifically by reducing the mortality rate, deformity rate, and cardiotoxicity of zebrafish; abnormal phenotypes were mainly observed in zebrafish heart abnormalities, circulatory system abnormalities, and the secretion of flocculent substances after drug stress. No abnormalities were observed in the brain (brain shrinkage, brain degeneration), eyes (shrinkage), liver (enlargement, shrinkage / absence, degeneration), yolk sac (delayed absorption), kidneys (renal edema), intestines (abnormalities), muscles / segments (degeneration), or behavior (abnormalities), as shown in Table 2.1 and Figure 1.

[0477] Table 2.1 Experimental results of triglyceride-based chemotherapy drug carriers that enhance detoxification and efficacy in alleviating cisplatin toxicity (n = 30)

[0478]

[0479] Figure 1A and Figure 1B Toxicity of cisplatin-treated tumor-bearing zebrafish after 72 hours of treatment with a triglyceride structure of a chemotherapy drug carrier that enhances detoxification and efficacy. Figure 1A Typical diagram of zebrafish toxicity; Figure 1B The bar charts for each phenotype are presented. Statistical differences are determined using ANOVA: * represents p < 0.05, ** represents p < 0.01, and *** represents p < 0.001.

[0480] 4.2.2 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Effects in Alleviating Cyclophosphamide Toxicity

[0481] Under the experimental conditions, the mortality rate of zebrafish in the cyclophosphamide 8 mM group was 0%, the deformity rate was 100%, and the average heart rate was 42.7 beats / 20 s; the mortality rate of zebrafish in the group with a 250 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 8 mM cyclophosphamide was 0%, the deformity rate was 83%, and the average heart rate was 42.8 beats / 20 s; the mortality rate of zebrafish in the group with a 500 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 8 mM cyclophosphamide was 0%, the deformity rate was 73%, and the average heart rate was 43.0 beats / 20 s; the mortality rate of zebrafish in the group with a 1000 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 8 mM cyclophosphamide was 0%, the deformity rate was 73%, and the average heart rate was 42.8 beats / 20 s. The presence of triglycerides, a carrier structure for detoxifying and enhancing the efficacy of chemotherapeutic drugs, indicates that cyclophosphamide can help improve cancer chemotherapy, specifically by reducing the rate of deformities in zebrafish. Abnormal phenotypes observed mainly included swim bladder loss, delayed yolk sac absorption, lateral curvature, short stature, and mandibular deformity. No abnormalities were observed in the heart (pericardial edema, arrhythmia), circulatory system (accelerated blood flow, slowed blood flow / absence), hemorrhage and thrombosis, brain (smaller brain, brain degeneration), eyes (smaller eyes), liver (enlarged, smaller / absent, degeneration), kidneys (renal edema), intestines (abnormalities), muscles / segments (degeneration), or behavior (abnormalities). See Table 2.2 and... Figure 2A , Figure 2B .

[0482] Table 2.2 Experimental results of triglyceride-based chemotherapy drug carriers that enhance detoxification and efficacy in alleviating cyclophosphamide toxicity (n = 30)

[0483]

[0484] Figure 2A and Figure 2B Toxicity of cyclophosphamide treatment in zebrafish with tumor-bearing zebrafish after 72 hours of treatment with a triglyceride-based chemotherapy drug carrier structure that enhances detoxification and efficacy. Figure 2A Typical diagram of zebrafish toxicity; Figure 2B The bar charts for each phenotype are presented. Statistical differences are determined using ANOVA: ** represents p < 0.01, *** represents p < 0.001.

[0485] 4.2.3 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Effects in Alleviating Methotrexate Toxicity

[0486] Under the experimental conditions, the mortality rate of zebrafish in the 800 μM methotrexate group was 0%, the deformity rate was 87%, and the average heart rate was 42.7 beats / 20 s; the mortality rate of zebrafish in the 250 μg / mL triglyceride + 800 μM methotrexate group was 0%, the deformity rate was 80%, and the average heart rate was 42.7 beats / 20 s; the mortality rate of zebrafish in the 500 μg / mL triglyceride + 800 μM methotrexate group was 0%, the deformity rate was 87%, and the average heart rate was 43.0 beats / 20 s; the mortality rate of zebrafish in the 1000 μg / mL triglyceride + 800 μM methotrexate group was 0%, the deformity rate was 57%, and the average heart rate was 42.9 beats / 20 s. The presence of triglycerides, a detoxifying and enhancing chemotherapeutic drug carrier structure, indicates that methotrexate can help improve the efficacy of cancer chemotherapy, specifically by reducing the deformity rate in zebrafish. Abnormal phenotypes observed mainly included swim bladder loss, delayed yolk sac absorption, lateral bending of the body, and liver degeneration. No abnormalities were observed in the heart (pericardial edema, abnormal heart rate), circulatory system (increased blood flow, decreased blood flow / absence), hemorrhage and thrombosis, brain (smaller brain, brain degeneration), eyes (smaller eyes), liver (enlarged, smaller / absent liver), kidneys (renal edema), intestines (abnormalities), muscles / segments (degeneration), or behavioral abnormalities. See Table 2.3 and... Figure 3A , Figure 3B .

[0487] Table 2.3 Results of experiments on the detoxification and efficacy enhancement of chemotherapy drug carriers, specifically triglycerides, in alleviating methotrexate toxicity (n = 30).

[0488]

[0489] Figure 3A and Figure 3B Toxicity of triglyceride-based chemotherapy drug carrier structure after 72 hours of methotrexate treatment in zebrafish with tumors; Figure 3A Typical diagram of zebrafish toxicity; Figure 3B Bar charts for each phenotype, statistically significant differences were determined using ANOVA: *** represents p < 0.001.

[0490] 4.2.4 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Effects in Alleviating Clofazimine Toxicity

[0491] Under the experimental conditions, the mortality rate of zebrafish in the 24 μM chlorpromazine group was 3%, the deformity rate was 60%, and the average heart rate was 42.4 beats / 20 s; the mortality rate of zebrafish in the group with 250 μg / mL of the chemotherapeutic drug carrier structure (triglycerides) + 24 μM chlorpromazine was 0%, the deformity rate was 60%, and the average heart rate was 42.6 beats / 20 s; the mortality rate of zebrafish in the group with 500 μg / mL of the chemotherapeutic drug carrier structure (triglycerides) + 24 μM chlorpromazine was 0%, the deformity rate was 57%, and the average heart rate was 42.3 beats / 20 s; the mortality rate of zebrafish in the group with 1000 μg / mL of the chemotherapeutic drug carrier structure (triglycerides) + 24 μM chlorpromazine was 0%, the deformity rate was 23%, and the average heart rate was 42.7 beats / 20 s. The presence of triglycerides, a carrier structure for detoxifying and enhancing the efficacy of chemotherapeutic drugs, indicates that chlorofazimine can help improve cancer chemotherapy, specifically by reducing the deformity rate in zebrafish. Abnormal phenotypes observed mainly included swim bladder loss, delayed yolk sac absorption, body curvature, liver degeneration, and muscle degeneration. No abnormalities were observed in the heart (pericardial edema, arrhythmia), circulatory system (accelerated blood flow, slowed blood flow / absence), hemorrhage and thrombosis, brain (small brain, brain degeneration), eyes (small eyes), kidneys (renal edema), intestines (abnormalities), or behavior (abnormalities). See Table 2.4 and... Figure 4A , Figure 4B .

[0492] Table 2.4 Results of experiments on the detoxification and efficacy enhancement of chemotherapy drug carriers, specifically triglycerides, to alleviate clofazimine toxicity (n = 30)

[0493]

[0494] Figure 4A and Figure 4B Toxicity of a chemotherapy drug carrier structure with detoxification and efficacy enhancement, specifically triglyceride-treated clofazimine for tumor treatment in zebrafish after 72 hours; Figure 4A Typical diagram of zebrafish toxicity; Figure 4B Bar charts for each phenotype, statistically significant differences were determined using ANOVA: *** represents p < 0.001.

[0495] 4.2.5 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Effects in Alleviating Tamoxifen Toxicity

[0496] Under the experimental conditions, the mortality rate of zebrafish in the 10 μM tamoxifen group was 3%, the deformity rate was 100%, and the average heart rate was 42.3 beats / 20 s; the mortality rate of zebrafish in the group with 250 μg / mL of 250 μg / mL 250 μm + 10 μM tamoxifen was 0%, the deformity rate was 77%, and the average heart rate was 42.4 beats / 20 s; the mortality rate of zebrafish in the group with 500 μg / mL 500 μg / mL 500 μm + 10 μM tamoxifen was 0%, the deformity rate was 60%, and the average heart rate was 42.7 beats / 20 s; the mortality rate of zebrafish in the group with 1000 μg / mL 10 μM 10 μM 10 μM tamoxifen was 0%, the deformity rate was 63%, and the average heart rate was 42.8 beats / 20 s. The presence of triglycerides, a carrier structure for detoxifying and enhancing the efficacy of chemotherapeutic drugs, indicates that tamoxifen can help improve cancer chemotherapy, specifically by reducing the rate of deformities in zebrafish. Abnormal phenotypes observed mainly included swim bladder loss, delayed yolk sac absorption, mandibular deformity, muscle degeneration, scoliosis, liver degeneration, pericardial edema, and microphthalmia. No abnormalities were observed in the heart (abnormal heart rate), circulatory system (increased or decreased blood flow), hemorrhage and thrombosis, brain (microphthalmia, brain degeneration), kidneys (renal edema), intestines (abnormalities), or behavioral abnormalities. See Table 2.5 and... Figure 5A , Figure 5B .

[0497] Table 2.5 Results of experiments on the detoxification and efficacy enhancement of chemotherapy drug carriers, specifically triglycerides, in alleviating tamoxifen toxicity (n = 30).

[0498]

[0499] Figure 5A and Figure 5B Toxicity of tamoxifen-treated tumor-bearing zebrafish after 72 hours of treatment with a triglyceride structure of a chemotherapy drug carrier that enhances detoxification and efficacy. Figure 5A Typical diagram of zebrafish toxicity; Figure 5B The bar charts for each phenotype were analyzed using independent t-tests to determine statistical differences: *** represents p < 0.001.

[0500] 4.2.6 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Effects in Alleviating Doxorubicin Hydrochloride Toxicity

[0501] Under the experimental conditions, the mortality rate of zebrafish in the 100 μM doxorubicin hydrochloride group was 20%, the deformity rate was 97%, and the average heart rate was 42.5 beats / 20 s; the mortality rate of zebrafish in the group with 250 μg / mL of the chemotherapeutic drug carrier structure (triglyceride) + 100 μM doxorubicin hydrochloride was 7%, the deformity rate was 97%, and the average heart rate was 42.6 beats / 20 s; the mortality rate of zebrafish in the group with 500 μg / mL of the chemotherapeutic drug carrier structure (triglyceride) + 100 μM doxorubicin hydrochloride was 3%, the deformity rate was 97%, and the average heart rate was 42.8 beats / 20 s; and the mortality rate of zebrafish in the group with 1000 μg / mL of the chemotherapeutic drug carrier structure (triglyceride) + 100 μM doxorubicin hydrochloride was 0%, the deformity rate was 93%, and the average heart rate was 42.9 beats / 20 s. The presence of triglycerides, a detoxifying and enhancing chemotherapeutic drug carrier structure, indicates that adjuvants can help improve the efficacy of doxorubicin hydrochloride in cancer chemotherapy, specifically by reducing the rate of deformities in zebrafish (delayed yolk sac absorption, mandibular deformity, muscle degeneration, shortened body length, liver degeneration, and pericardial edema). Abnormal phenotypes observed mainly included swim bladder loss, delayed yolk sac absorption, mandibular deformity, muscle degeneration, shortened body length, lateral curvature, liver degeneration, pericardial edema, and microphthalmia. No abnormalities were observed in the heart (abnormal heart rate), circulatory system (accelerated blood flow, slowed blood flow / absence), hemorrhage and thrombosis, brain (microphthalmia, brain degeneration), kidneys (renal edema), intestines (abnormalities), or behavioral abnormalities. See Table 2.6 and... Figure 6A , Figure 6B .

[0502] Table 2.6 Results of experiments on the detoxification and efficacy enhancement of chemotherapy drug carriers, specifically triglycerides, in alleviating the toxicity of doxorubicin hydrochloride (n=30).

[0503]

[0504] Figure 6A and Figure 6B Toxicity of doxorubicin hydrochloride treated with a triglyceride-based chemotherapy drug carrier structure for 72 hours after treatment with tumor-bearing zebrafish; Figure 6A Typical diagram of zebrafish toxicity; Figure 6B The bar charts for each phenotype are presented. Statistical differences are determined using ANOVA: ** represents p < 0.01, *** represents p < 0.001.

[0505] 4.2.7 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Efficacy in Alleviating Imatinib Toxicity

[0506] Under the experimental conditions, the mortality rate of zebrafish in the 60 μM imatinib group was 0%, the deformity rate was 57%, and the average heart rate was 42.5 beats / 20 s; the mortality rate of zebrafish in the 250 μg / mL imatinib-60 μM imatinib-detoxification-enhanced chemotherapy drug carrier group was 0%, the deformity rate was 43%, and the average heart rate was 42.5 beats / 20 s; the mortality rate of zebrafish in the 500 μg / mL imatinib-50 μM imatinib-60 μM imatinib-detoxification-enhanced chemotherapy drug carrier group was 0%, the deformity rate was 30%, and the average heart rate was 42.8 beats / 20 s; the mortality rate of zebrafish in the 1000 μg / mL imatinib-100 μM imatinib-60 μM imatinib-detoxification-enhanced chemotherapy drug carrier group was 0%, the deformity rate was 17%, and the average heart rate was 42.9 beats / 20 s. The presence of triglycerides, a carrier structure for detoxifying and enhancing the efficacy of chemotherapeutic drugs, indicates that imatinib can help improve cancer chemotherapy, specifically by reducing the deformity rate in zebrafish. Abnormal phenotypes observed mainly included swim bladder loss and delayed yolk sac absorption in zebrafish. No abnormalities were observed in the heart (abnormal heart rate), circulatory system (accelerated, slowed / absent blood flow), hemorrhage and thrombosis, brain (small brain, brain degeneration), kidneys (renal edema), intestines (abnormalities), or behavioral abnormalities. See Table 2.7 and... Figure 7A , Figure 7B .

[0507] Table 2.7 Results of experiments on the detoxification and efficacy enhancement of chemotherapy drug carrier structures using triglycerides to alleviate imatinib toxicity (n = 30)

[0508]

[0509] Figure 7A and Figure 7B Toxicity of imatinib-treated tumor zebrafish after 72 hours of treatment with triglyceride-based chemotherapy drug carrier structure; Figure 7A Typical toxicity diagram of zebrafish; Figure 7B Bar chart of each phenotype. Statistical differences were analyzed using ANOVA: * represents p < 0.05, *** represents p < 0.001.

[0510] 4.2.8 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Effects in Alleviating Etoposide Toxicity

[0511] Under the experimental conditions, the mortality rate of zebrafish in the etoposide 8 mM group was 0%, the deformity rate was 60%, and the average heart rate was 42.9 beats / 20 s; the mortality rate of zebrafish in the group with 250 μg / mL of the chemotherapeutic drug carrier structure (triglycerides) + 8 mM etoposide was 0%, the deformity rate was 33%, and the average heart rate was 42.8 beats / 20 s; the mortality rate of zebrafish in the group with 500 μg / mL of the chemotherapeutic drug carrier structure (triglycerides) + 8 mM etoposide was 0%, the deformity rate was 30%, and the average heart rate was 42.8 beats / 20 s; the mortality rate of zebrafish in the group with 1000 μg / mL of the chemotherapeutic drug carrier structure (triglycerides) + 8 mM etoposide was 0%, the deformity rate was 30%, and the average heart rate was 42.9 beats / 20 s; and the mortality rate of zebrafish in the group with 1000 μg / mL of the chemotherapeutic drug carrier structure (triglycerides) + 8 mM etoposide was 0%, the deformity rate was 30%, and the average heart rate was 42.9 beats / 20 s. The presence of triglycerides, a carrier structure for detoxifying and enhancing the efficacy of chemotherapy drugs, indicates that etoposide can help improve cancer chemotherapy, specifically by reducing the deformity rate in zebrafish. Abnormal phenotypes observed mainly included swim bladder loss and delayed yolk sac absorption in zebrafish. No abnormalities were observed in the heart (pericardial edema, arrhythmia), circulatory system (accelerated blood flow, slowed blood flow / absence), hemorrhage and thrombosis, brain (smaller brain, brain degeneration), eyes (smaller eyes), liver (enlarged, smaller / absent, degeneration), kidneys (renal edema), intestines (abnormalities), trunk / tail / notochord (curvature), muscles / segments (degeneration), or behavior (abnormalities). See Table 2.8 and... Figure 8A , Figure 8B .

[0512] Table 2.8 Results of experiments on the detoxification and efficacy enhancement of chemotherapy drug carrier structures and the reduction of etoposide toxicity by triglycerides (n = 30)

[0513]

[0514] Figure 8A and Figure 8B Toxicity of etoposide treated with triglyceride, a chemotherapeutic drug carrier structure, after 72 hours of treatment with tumor-bearing zebrafish; Figure 8A: Typical toxicity of zebrafish; Figure 8B: Bar chart of each phenotype. Statistical analysis of variance was performed: *** represents p < 0.001.

[0515] 4.2.9 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Effects in Alleviating Paclitaxel Toxicity

[0516] Under the experimental conditions, the mortality rate of zebrafish in the paclitaxel 400 μM group was 0%, the deformity rate was 87%, and the average heart rate was 42.4 beats / 20s; the mortality rate of zebrafish in the group with a 250 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 400 μM paclitaxel was 0%, the deformity rate was 33%, and the average heart rate was 42.5 beats / 20s; the mortality rate of zebrafish in the group with a 500 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 400 μM paclitaxel was 0%, the deformity rate was 17%, and the average heart rate was 42.5 beats / 20s; the mortality rate of zebrafish in the group with a 1000 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 400 μM paclitaxel was 0%; and the mortality rate of zebrafish in the group with a 1000 μg / mL triglyceride carrier structure for detoxification and enhancement combined with 400 μM paclitaxel was 0%. The mortality rate of zebrafish in the μM group was 0%, the deformity rate was 10%, and the average heart rate was 42.6 beats / 20s. This indicates that the triglyceride structure, a detoxifying and enhancing chemotherapeutic drug carrier, can help improve the efficacy of paclitaxel in cancer chemotherapy, specifically by reducing the deformity rate in zebrafish. Abnormal phenotypes observed mainly included swim bladder loss and delayed yolk sac absorption in zebrafish. No abnormalities were observed in the heart (pericardial edema, arrhythmia), circulatory system (accelerated blood flow, slowed blood flow / absence), hemorrhage and thrombosis, brain (smaller brain, brain degeneration), eyes (smaller), liver (enlarged, smaller / absent, degeneration), kidneys (renal edema), intestines (abnormalities), trunk / tail / notochord (curvature), muscles / segments (degeneration), or behavior (abnormalities). See Table 2.9 and... Figure 9A , Figure 9B .

[0517] Table 2.9 Results of experiments on the detoxification and efficacy enhancement of chemotherapy drug carriers, specifically triglycerides, in alleviating paclitaxel toxicity (n = 30).

[0518]

[0519] Figure 9A and Figure 9B Toxicity of paclitaxel-treated zebrafish with tumor-bearing zebrafish after 72 hours of treatment with a triglyceride-based chemotherapy drug carrier structure that enhances detoxification and efficacy. Figure 9A Typical diagram of zebrafish toxicity; Figure 9B Bar charts for each phenotype, statistically significant differences were determined using ANOVA: *** represents p < 0.001.

[0520] 4.2.10 Detoxification and Enhancement of Chemotherapy Drug Carrier Structure: Triglycerides and Their Effects in Alleviating 5-FU Toxicity

[0521] Under the experimental conditions, the mortality rate of zebrafish in the 32 mM 5-FU group was 0%, the deformity rate was 73%, and the average heart rate was 42.4 beats / 20s; the mortality rate of zebrafish in the 250 μg / mL + 32 mM 5-FU group was 0%, the deformity rate was 50%, and the average heart rate was 42.5 beats / 20s; the mortality rate of zebrafish in the 500 μg / mL + 32 mM 5-FU group was 0%, the deformity rate was 37%, and the average heart rate was 42.6 beats / 20s; the mortality rate of zebrafish in the 1000 μg / mL + 32 mM 5-FU group was 0%; and the average heart rate of zebrafish in the 1000 μg / mL + 32 mM 5-FU group was 37%. The mortality rate of zebrafish in the mM group was 0%, the deformity rate was 27%, and the average heart rate was 42.5 beats / 20s. This indicates that the detoxification and efficacy-enhancing chemotherapeutic drug carrier structure triglycerides can help improve the cancer chemotherapy of 5-FU, specifically by reducing the deformity rate of zebrafish. Abnormal phenotypes observed mainly included swim bladder loss, delayed yolk sac absorption, and liver degeneration. No abnormalities were observed in the heart (pericardial edema, arrhythmia), circulatory system (accelerated blood flow, slowed blood flow / absence), hemorrhage and thrombosis, brain (small brain, brain degeneration), eyes (small eyes), kidneys (renal edema), intestines (abnormalities), trunk / tail / notochord (bending), muscles / segments (degeneration), or behavior (abnormalities). See Table 2.10 and Figure 10A. Figure 10B .

[0522] Table 2.10 Results of experiments on the detoxification and efficacy enhancement of chemotherapy drug carrier structures, specifically triglycerides, in alleviating 5-FU toxicity (n = 30)

[0523]

[0524] Figure 10A and Figure 10B Toxicity of 5-FU treated with tumor-bearing zebrafish after 72 hours of treatment with a triglyceride structure of a chemotherapy drug carrier that enhances detoxification and efficacy. Figure 10A Typical diagram of zebrafish toxicity; Figure 10B Bar charts for each phenotype, statistically significant differences were determined using ANOVA: *** represents p < 0.001.

[0525] 4.3 Improve white blood cell levels (neutrophils) after chemotherapy

[0526] The results showed that, after 48 h of treatment, compared with the model control group, the chemotherapeutic drug carrier structure triglyceride significantly increased the number of neutrophils in the zebrafish tail vein. Based on the formula for calculating the efficacy in improving white blood cell levels after chemotherapy, the efficacy of the chemotherapeutic drug carrier structure triglyceride in improving white blood cell levels (neutrophils) after chemotherapy was 51.74%. See Table 3 for details. Figure 11A , Figure 11B .

[0527] Table 3 Results of tail vein neutrophil count experiment (n = 10)

[0528]

[0529] Compared with the model control group, *** represents p < 0.001.

[0530] Figure 11A and Figure 11B The number of neutrophils in the tail vein of zebrafish after treatment with triglycerides as a detoxifying and efficacy-enhancing chemotherapy drug carrier structure for 48 h. Figure 11A Typical image of neutrophil count in zebrafish tail vein after sample processing (red dashed box indicates the analysis site). Figure 11B Number of neutrophils in the tail vein of zebrafish after sample processing. Statistical differences were analyzed using independent t-tests: *** represents p < 0.001.

[0531] 4.4 Improve white blood cell (T cell) levels after chemotherapy

[0532] The results showed that, 48 h after treatment, compared with the model control group, the chemotherapeutic drug carrier structure triglyceride significantly increased the fluorescence intensity of thymic T cells in zebrafish. Based on the formula for calculating the efficacy in improving white blood cell levels after chemotherapy, the efficacy of the chemotherapeutic drug carrier structure triglyceride in improving white blood cell (T cell) levels after chemotherapy was 124.11%, suggesting its immune-enhancing effect. See Table 4 for details. Figure 12A , Figure 12B .

[0533] Table 4 Results of thymic T cell fluorescence intensity assay (n = 10)

[0534]

[0535] Compared with the model control group, * represents p < 0.05 and ** represents p < 0.01.

[0536] Figure 12A and Figure 12B Fluorescence intensity of thymic T cells in zebrafish after treatment with triglyceride structure for 48 h to enhance detoxification and efficacy of chemotherapy drugs. Figure 12A Typical fluorescence intensity of T cells in zebrafish thymus after sample processing (red dashed box indicates the analysis site). Figure 12B Fluorescence intensity (pixels) of zebrafish thymus T cells after sample treatment. Statistical differences were analyzed using independent t-tests: * represents p < 0.05, ** represents p < 0.01.

[0537] 4.5 Improve white blood cell levels (macrophages) after chemotherapy

[0538] The results showed that, after 48 hours of treatment, compared with the model control group, the chemotherapeutic drug carrier structure triglyceride significantly increased the number of macrophages in the zebrafish tail vein. Based on the formula for calculating the efficacy in improving white blood cell levels after chemotherapy, the efficacy of the chemotherapeutic drug carrier structure triglyceride in improving white blood cell levels (macrophages) after chemotherapy was 54.95%, suggesting that it has an immune-enhancing effect. See Table 5 for details. Figure 13A , Figure 13B .

[0539] Table 5. Results of tail vein macrophage count experiment (n = 10)

[0540]

[0541] Compared with the model control group, *** represents p < 0.001.

[0542] Figure 13A and Figure 13B The number of macrophages in the tail vein of zebrafish after treatment with triglyceride, a chemotherapy drug carrier structure that enhances detoxification and efficacy, for 48 h. Figure 13A Typical image of the number of macrophages in the tail vein of zebrafish after sample processing (red box indicates the analysis site). Figure 13B Number of macrophages in the tail vein of zebrafish after sample treatment. Statistical differences were analyzed using independent t-tests: *** represents p < 0.001.

[0543] 4.6 Improves red blood cell levels after chemotherapy

[0544] The results showed that, compared with the model control group, treatment with the detoxifying and enhancing chemotherapeutic drug carrier structure triglyceride significantly increased the staining intensity of erythrocytes in zebrafish hearts, indicating that it had the effect of improving erythrocyte levels after chemotherapy. See Table 6 for details. Figure 14A , Figure 14B .

[0545] Table 6 Results of cardiac erythrocyte staining intensity test (n = 10)

[0546]

[0547] Compared with the model control group, *** represents p < 0.001.

[0548] Figure 14A and Figure 14B The staining intensity of erythrocytes from the heart of zebrafish after treatment with triglycerides for 48 h to enhance the detoxification and efficacy of chemotherapy drug carriers. Figure 14A Typical image of red blood cell staining intensity in zebrafish heart after sample processing (red dashed box indicates the analysis area). Figure 14BIntensity of erythrocyte staining in zebrafish hearts (pixels) after sample processing. Statistical differences were analyzed using independent t-tests: *** represents p < 0.001.

[0549] 4.7 Improve sepsis

[0550] The results showed that, compared with the model control group, treatment with the detoxifying and enhancing chemotherapy drug carrier triglyceride significantly reduced the number of neutrophils in the zebrafish heart. According to the formula for calculating the efficacy in improving sepsis, the detoxifying and enhancing chemotherapy drug carrier triglyceride had an efficacy of 54.05% in improving sepsis, indicating that it has a clear positive effect on alleviating sepsis-related inflammation. See Table 7 for details. Figure 15A , Figure 15B .

[0551] Table 7 Results of cardiac neutrophil count experiment (n = 10)

[0552]

[0553] Compared with the model control group, *** represents p < 0.001.

[0554] Figure 15 A and Figure 15B The number of neutrophils in the heart of zebrafish after treatment with triglycerides, a carrier structure for detoxification and enhanced efficacy; Figure 15 A Typical diagram of the number of neutrophils in the heart of zebrafish after sample treatment (the yellow dashed box is the area of ​​analysis). Figure 15B Number of neutrophils in the heart of zebrafish after sample treatment. Statistical differences were analyzed using independent t-tests: *** represents p < 0.001.

[0555] 4.8 Preventing hair loss

[0556] The results showed that, compared with the model control group, zebrafish treated with the detoxifying and enhancing chemotherapy drug carrier triglyceride structure exhibited increased blood flow velocity, indicating its anti-hair loss effect. See Table 8 for details. Figure 16 .

[0557] Table 8. Results of blood flow velocity experiments (n = 10)

[0558]

[0559] Compared with the model control group, * represents p < 0.05, and *** represents p < 0.001.

[0560] Figure 16Blood flow velocity in zebrafish after treatment with triglyceride-based chemotherapy drug carriers for detoxification and enhanced efficacy; blood flow velocity (μm / s) in zebrafish after sample treatment. Statistical differences were analyzed using independent t-tests: * represents p < 0.05, *** represents p < 0.001.

[0561] 4.9 Anti-tumor activity (HL-60 myeloid tumor cells)

[0562] The results showed that after 48 h of treatment, the fluorescence intensity of zebrafish myeloid tumor cells HL-60 containing the detoxifying and enhancing chemotherapeutic drug carrier triglyceride was significantly lower than that of the model control group. A concentration of 2000 μg / mL of the detoxifying and enhancing chemotherapeutic drug carrier triglyceride reduced the fluorescence intensity of zebrafish myeloid tumor cells by 23%, revealing that the detoxifying and enhancing chemotherapeutic drug carrier triglyceride has anti-tumor effects. (See Table 9 for details.) Figure 17A , Figure 17B .

[0563] Table 9. Experimental results of triglyceride-based chemotherapy drug carrier structures with detoxification and efficacy enhancement in antitumor (myeloid) therapy (n = 10)

[0564]

[0565] * indicates p < 0.05 compared with the model control group.

[0566] Figure 17A and Figure 17B Fluorescence intensity of zebrafish myeloid tumor cells after treatment with triglyceride structure of chemotherapy drug carrier for 48 h for detoxification and efficacy enhancement. Figure 17A Typical fluorescence intensity of zebrafish myeloid tumor cells after treatment with triglyceride, a structure that enhances the detoxification and efficacy of chemotherapy drugs. Figure 17B Fluorescence intensity (pixels) of zebrafish myeloid tumor cells after treatment with triglyceride, a chemotherapy drug carrier structure that enhances detoxification and efficacy. Statistical differences were analyzed using independent t-tests: * indicates p < 0.05.

[0567] 4.10 Anti-tumor (lymphoma cell jurachatin)

[0568] The results showed that after 48 h of treatment, the fluorescence intensity of zebrafish lymphoma cells (jurkat) containing the detoxifying and enhancing chemotherapeutic drug carrier triglyceride was significantly lower than that of the model control group. A concentration of 2000 μg / mL of the detoxifying and enhancing chemotherapeutic drug carrier triglyceride reduced the fluorescence intensity of zebrafish lymphoma cells by 30%, revealing that the detoxifying and enhancing chemotherapeutic drug carrier triglyceride has antitumor effects. (See Table 10 for details.) Figure 18A , Figure 18B .

[0569] Table 10. Experimental results of triglyceride-based chemotherapy drug carrier structures with detoxification and efficacy enhancement (n = 10)

[0570]

[0571] Compared with the model control group, ** indicates p < 0.01.

[0572] Figure 18A and Figure 18B Fluorescence intensity of zebrafish lymphoma cells after treatment with triglyceride structure of chemotherapy drug carrier for 48 h for detoxification and efficacy enhancement. Figure 18A Typical fluorescence intensity of zebrafish lymphoma cells after treatment with triglyceride-based chemotherapy drug carrier structure for detoxification and efficacy enhancement; Figure 18B Fluorescence intensity (pixels) of zebrafish lymphoma cells after treatment with triglyceride-based detoxifying and efficacy-enhancing chemotherapy drug carriers. Statistical differences were analyzed using independent t-tests: ** represents p < 0.01.

[0573] V. Experimental Conclusions

[0574] Under the experimental conditions, the detoxifying and enhancing chemotherapeutic drug carrier structure triglyceride showed clear efficacy in alleviating the toxicity of cisplatin, cyclophosphamide, methotrexate, clofazimine, tamoxifen, doxorubicin hydrochloride, imatinib, etoposide, paclitaxel, and 5-FU. This detoxifying and enhancing chemotherapeutic drug carrier structure triglyceride also showed clear efficacy in improving white blood cell and red blood cell levels after chemotherapy, improving sepsis, and anti-tumor effects. Furthermore, the chemotherapeutic (drug) structure lipid had anti-hair loss effects, specifically by increasing blood flow velocity in zebrafish. In an immunodeficiency model, this sample significantly increased the number of neutrophils and macrophages in the zebrafish tail vein and enhanced the fluorescence intensity of thymic T cells and the staining intensity of cardiac red blood cells, with efficacy rates of 51.74%, 124.11%, 54.95%, and 46.48% for neutrophils, T cells, macrophages, and cardiac red blood cells, respectively. In a sepsis model, this sample significantly reduced the number of cardiac neutrophils in zebrafish, with an efficacy value of 54.05%. In the anti-tumor model, the sample reduced the fluorescence intensity of zebrafish myeloid tumor cells by 23% and zebrafish lymphoma cells by 30%, respectively.

[0575] The technical features of the above-described embodiments and examples can be combined in any suitable manner. For the sake of brevity, not all possible combinations of the technical features in the above-described embodiments and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0576] The embodiments described above are merely illustrative of several implementation methods of this application, intended to facilitate a detailed understanding of the technical solutions of this application, but should not be construed as limiting the scope of protection of the patent application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the scope of protection of this application. Furthermore, it should be understood that after reading the above teachings of this application, those skilled in the art can make various alterations or modifications to this application, and the equivalent forms obtained also fall within the scope of protection of this application. It should also be understood that technical solutions obtained by those skilled in the art based on the technical solutions provided in this application through logical analysis, reasoning, or limited experimentation are all within the scope of protection of the appended claims. Therefore, the scope of protection of this patent application should be determined by the content of the appended claims, and the specification and drawings can be used to interpret the content of the claims.

Claims

1. A method for preparing a structural triglyceride composition, characterized in that, The preparation method includes the following steps: Mixed oil 1 and lipase 1 undergo a first transesterification reaction to prepare product 1; and, Mixed oilseed 2 and lipase 2 undergo a second transesterification reaction to deodorize and inactivate the enzyme, preparing a structured triglyceride composition; wherein... The oil 1 comprises highly unsaturated fatty acids and glycerol; The oilseed 2 includes the product 1, γ-linolenic acid, nervonic acid, and pinolenic acid; Optionally, the highly unsaturated fatty acids are added in the form of one or more of fish oil extracts, reduced fish oil, and polyene fish oil; Optionally, the γ-linolenic acid is added in the form of one or more of borage seed oil, evening primrose oil, blackcurrant oil, and fermented γ-linolenic acid; Optionally, the nervonic acid is added in the form of one or more of the following: *Sapindus mukorossi* oil, *Acer truncatum* seed oil, and *Gnaphalium affine*. Optionally, the pinolenic acid is added in the form of pine nut oil.

2. The method for preparing the structured triglyceride composition according to claim 1, characterized in that, The preparation method satisfies one or more of the following conditions: (A1) By weight, the oil 1 comprises: 8 to 20 parts of the polyene fish oil and 0.5 to 13 parts of glycerol; (A2) The amount of lipase 1 added is 3% to 8% of the weight of oil 1; (A3) The lipase 1 includes an immobilized lipase; and, (A4) The conditions for the first transesterification reaction include: vacuum degree of 50~200 Pa, temperature of 55~70℃, and time of 10~28h; Optionally, the lipase 1 includes one or more of the following: modified Aspergillus oryzae immobilized lipase, Candida antarcticis immobilized lipase, and IMNE0100 immobilized lipase.

3. The method for preparing the structured triglyceride composition according to any one of claims 1 to 2, characterized in that, The preparation method satisfies one or more of the following conditions: (A5) By weight, the oilseed 2 comprises: 2.5 to 4.5 parts of the product 1, 4.5 to 6.0 parts of borage seed oil, 0.2 to 1 part of pine nut oil and 0.2 to 2 parts of *Sapindus mukorossi* oil; or, 2.5 to 4.5 parts of the product 1, 4.5 to 6.0 parts of borage seed oil and 0.2 to 1.5 parts of *Acer truncatum* seed oil; (A6) The amount of lipase 2 added is 3% to 8% of the weight of the oilseed 2; (A7) The lipase 2 includes an immobilized lipase; and, (A8) The conditions for the second transesterification reaction include: vacuum degree of 5~200 Pa, temperature of 55~70℃, and time of 20~26 h; Optionally, the lipase 2 includes one or more of the following: modified Aspergillus oryzae immobilized lipase, Candida antarcticis immobilized lipase, and IMNE0100 immobilized lipase.

4. A structural triglyceride composition, characterized in that, Prepared by the preparation method according to any one of claims 1 to 3.

5. The use of structured lipids as detoxifying and enhancing agents for chemotherapy drugs; The structural lipids include one or more of structural lipids B1 to structural lipids B4; Structured lipid B1 is the structured triglyceride composition according to claim 4; Structural lipid B2 is a polyunsaturated fatty acid structural lipid, prepared by the following method: (1) Transesterification reaction: The raw materials and transesterification enzyme are reacted in a reactor to obtain the reaction product. The vacuum conditions are 50~200Pa, the reaction temperature is 40~90℃, and the reaction time is 8~48h. (2) Refining reaction: The reaction product obtained in step (1) is deacidified, deodorized and enzyme inactivated by distillation, and then finely filtered to obtain polyunsaturated fatty acid structure lipids. The raw materials include at least oils containing gamma-linolenic acid and oils containing eicosapentaenoic acid and docosahexaenoic acid; the raw materials also include one or more of the following: Acer truncatum seed oil, garlic fruit oil, pine nut oil, coconut oil, palm oil, and Moringa seed oil. Structural lipid B3 was prepared by the following method: Structured lipid B3 was obtained by reacting highly unsaturated fatty acids, glycerol, and transesterase. in, The highly unsaturated fatty acids are oils containing EPA and DHA; The reaction conditions are: vacuum, reaction temperature 50℃~80℃, and reaction time 15~48h; Structural lipid B4 is an 18-24 carbon polyunsaturated fatty acid structural lipid; optionally, the raw materials for preparing the 18-24 carbon polyunsaturated fatty acid structural lipid are selected from one or more of structural lipids containing linoleic acid, structural lipids containing γ-linolenic acid, structural lipids containing EPA, and structural lipids containing DHA. Optionally, the structural lipid B4 is prepared by the following method: Mixed oil 4 and lipase 4 undergo a fourth transesterification reaction to inactivate the enzyme and prepare structural lipid B4. The oilseed 4 includes borage seed oil, fish oil, and thistle seed oil; Optionally, the method for preparing the structural lipid B4 satisfies one or more of the following conditions: (B41) By weight, the oilseed 4 comprises 45-60 parts borage seed oil, 30-40 parts fish oil and 10-20 parts thistle seed oil; (B42) The lipase 4 includes an immobilized enzyme; (B43) The amount of lipase 4 added is 3.5% to 4.5% of the weight of the oil 4; (B44) The conditions for the fourth transesterification reaction include: vacuum degree of 50~200 Pa, temperature of 55~70℃, and time of 30~40 h; Optionally, the lipase 4 includes one or more of IMNE-100 immobilized lipase and Novozymes 435 immobilized lipase.

6. A composition, characterized in that, The composition comprises: Structural lipids, as defined in claim 5; and, Chemotherapy drugs; The composition is a combination drug composition or mixture.

7. The composition according to claim 6, characterized in that, The composition also contains a nutrient fortifier, which includes Haematococcus pluvialis oil. Optionally, the amount of Haematococcus pluvialis oil added is 1 to 3‰ of the weight of the structural lipid.

8. The composition according to claim 6, characterized in that, The weight ratio of the structural lipid to the chemotherapeutic drug is (96~100):(3~4).

9. The composition according to claim 6, characterized in that, The composition also contains an emulsifier; Optionally, the amount of the emulsifier added is 2% to 4% of the weight of the structural lipid or the composition; Optionally, the emulsifier includes one or more of the following: sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80), polyoxyethylene (20) sorbitan monooleate (Tween 80), polyoxyethylene (20) sorbitan monolaurate (Tween 20), mono- and diglycerides of fatty acids, polyglycerol fatty acids, polyethylene glycol fatty acids, and polyglycerol ricinoleate.

10. The composition according to claim 6, characterized in that, The composition also contains medium- and long-chain fatty acids; Optionally, the method for preparing the medium- and long-chain fatty acids includes: (a) The purified medium-chain fatty acid triglycerides and the purified 14-24 carbon long-chain fatty acid triglycerides were put into a reactor, lipase and vitamin E catalyst were added, and transesterification reaction was carried out at a temperature of 40-85℃, a vacuum of 5-200 Pa, for 15-34 h, and the reaction was terminated to obtain material 1. (b) The material 1 obtained in step (a) is purified at a temperature of 190~260°C with dry water vapor to remove acid, deodorize, remove medium chain residues and deactivate enzymes to obtain the target product, high-purity medium and long chain fatty acid oil. Optionally, the weight ratio of the structural lipid or the composition to the medium- and long-chain fatty acid oil is (1~9):(1~4).

Citation Information

Patent Citations

  • A method for preparing polyunsaturated fatty acid structured lipids

    CN109337939B

  • A method for preparing high-purity medium- and long-chain fatty acid oils

    CN109666541B

  • Preparation method of fatty acid structure lipid capable of resisting tumor growth and inhibiting cancer cell migration

    CN112941121A

  • Structural lipid and preparation method thereof, structural fat emulsion and structural fat emulsion preparation

    CN115976125A